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ABSTRACT 
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Hydrocephalus is a debilitating disease characterized by an increase in cerebrospinal fluid (CSF) 
in the brain, leading to increases in pressure that can ultimately result in death. Current treatments 
for hydrocephalus include only invasive brain surgery. Therefore, the need for a pharmaceutical 
therapy is great. In order to develop a suitable treatment, we first must be able to study the disease 
and the mechanisms by which it develops. By characterizing appropriate in vivo and in vitro 
models, we are better able to study this disease. In this thesis, the Wpk rat model and the PCP-R 
cell line are described as such appropriate models. 
 
In addition to suitable models, we also require a target for drug treatment. Transient Receptor 
Potential Vanilloid 4 (TRPV4) is a non-selective cation ion channel present in the main CSF-
producing organ in the brain, the choroid plexus (CP). Preliminary data suggest this channel plays 
a role in the development of hydrocephalus. In the following work, some of the mechanisms by 
which TRPV4 functions in the brain are also described, including through calcium-sensitive 
potassium channels and inflammation. 
 
From this research, we are able to achieve a better understanding of the function of TRPV4 and 
how it can affect the development and progression of hydrocephalus.  
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 INTRODUCTION 
1.1 Hydrocephalus 
Neurodegenerative diseases consist of a wide range of pathologies affecting neurons in the brain. 
In the majority of cases, these diseases are incurable as they progressively destroy neurons, leading 
to the debilitation of the patients affected by them. The most common of these diseases alter motor 
function and mental cognition (1). Some of these diseases include dementias, such as Alzheimer’s 
disease (AD), which is synonymous with a loss of function in memory, thinking and behavior, and 
Lewy body diseases, such as Parkinson’s disease (PD) which can lead to gait ataxias and motion 
tremors, and traumatic brain injury (TBI), caused by inflammation and hemorrhage due to a severe 
impact to the skull and/or brain (1, 2).  While all these diseases are different in their own right, 
they each can have similar symptoms, such as problems with mental function and gait 
abnormalities. Specifically, these diseases share a common effect, which is the enlargement of the 
ventricles. 
 
Hydrocephalus can be a devastating condition seen in numerous neurological diseases in adults as 
well as children. Characterized by a buildup of cerebrospinal fluid (CSF) in the ventricular space 
either due to under-absorption, over-production, or a blockage of CSF flow, hydrocephalus is also 
known as “water on the brain” and is seen in approximately 85 out of every 100,000 or 6.4 million 
individuals worldwide across all ages (3). Tumors, infection, head trauma, hemorrhage, genetic 
defects, inflammation, and neurogenerative disease can all be associated with the development of 
hydrocephalus (4-14). In these instances, there can be two different types of hydrocephalus: 
communicating and non-communicating. In communicating hydrocephalus, there is either an 
under-absorption or an over-production of CSF. While the choroid plexus is considered the main 
producer of CSF, other cells such as ependymal cells, the cells lining the ventricles, or cells in the 
subarachnoid space, another area of the brain where CSF flows can also contribute to fluid 
production. The relative contribution of these, particularly in disease states, is determined by the 
nature of the pathology. In non-communicating hydrocephalus, there is a blockage in the flow of 
CSF, usually in the aqueducts connecting the different ventricles. The subsequent increase in 
hydrostatic pressure from either form can lead to neuronal damage and cell death (14).  
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The most severe cases of the disorder occur in children with a prevalence of about 1 in every 1000 
live births (6). Because infant skulls are not yet ossified, the increase in fluid can cause doming of 
their skulls, leading to even more complications as the child develops. In adults and elderly patients, 
hydrocephalus is often seen as the poorly understood form called “normal pressure hydrocephalus” 
(NPH). This type of hydrocephalus shows increased ventricular size, but often the brain does not 
have an increase in intracranial pressure. However, the term “normal pressure” can be a misnomer 
as “intracranial pressure is not always normal in NPH” (15). This condition experiences symptoms 
similar to those of other neurological disorders including urinary incontinence, gait ataxia, 
progressive mental impairment and dementia. If caught in the early stages, NPH is considered 
“potentially reversible” (15). Often, NPH is misdiagnosed for the other neurological disorders with 
which it shares symptomatic similarities. As noted above, hydrocephalus can also be secondarily 
caused by other diseases such as TBI, PD, and AD. 
1.2 Hydrocephalus Treatment Options 
Currently, treatments for the disease include three main surgical methods. In endoscopic third 
ventriculostomy (ETV) the third ventricle is perforated to allow a bypass for blocked CFS in non-
communicating hydrocephalus. Surgical implantation of a shunt into the ventricles allows drainage 
of excess CSF from the affected areas to alternative cavities of the body for reabsorption. 
Cauterization of the choroid plexus, the main producer of CSF, sometimes in conjunction with 
ETV, can slow down the accumulation of fluid (14, 16, 17). However, ETVs can be associated 
with bleeding, fever, and, in 10-30% of cases, a closure of the third ventricle puncture (18). In 
neonatal patients, ETVs have extremely low survival rates in infants 3 months or younger. This 
rate only improves to about 64% by 6 months of age (14). In most cases, failure of an ETV means 
the necessity of a shunt (19). 
 
Cauterization of the choroid plexus is considered more effective than ETV alone and is most often 
performed on infants in developing countries where shunt infections are more prevalent and 
surgical care less available (20). However, this procedure is irreversible as it permanently destroys 
the majority of cells producing CSF, and the long-term effects are unknown. 
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Shunt implantation is the most common approved treatment. Still, due to children growing out of 
their shunts, shunt blockage, and infection, survival of a shunt lies around 70% at one-year post-
implantation and drops to as low as 40% ten years post-implantation (19). In the adult population, 
while lower than in children, there is still a substantial percentage of the patients in need of shunt 
revisions. Infections can occur in as many as 30% of patients (19). While a select group of elderly 
NPH patients, when diagnosed early, experienced a reversal of symptoms upon shunt implantation, 
older patients are particularly susceptible to developing subdural hemorrhage, infection, and other 
postsurgical complications after shunt placement, with the benefits declining over time (15). These 
issues with shunt use only lead to more surgeries which can be detrimental for the physical and 
mental health of the patient and the financial state of the family. Therefore, the need for a long-
term, efficient pharmaceutical treatment is critical to give these patients a more healthful, normal 
life. 
1.3 The Choroid Plexus and CSF Flow 
As previously stated, it is estimated that about 80% of CSF is produced by the choroid plexus (CP) 
with the remaining 20% coming from the brain parenchyma and interstitial fluid (21, 22). The CP 
is present in the third, fourth, and both lateral ventricles and is composed of a high-resistance 
barrier epithelium covering a network of leaky capillaries which allow ions and water to enter the 
space between the capillaries and the epithelium (21). However, these ions and water are strictly 
regulated by the CP epithelial (CPE) cells from entering the ventricular space. Multiple ion 
channels and co-transporters on either membrane of the polarized epithelial cells control 
transepithelial ion flux in both directions. As ions move across the epithelium, water follows in 
order to maintain osmotic concentrations, thus producing CSF (21). Therefore, this regulation 
allows the CP to control the amount and composition of CSF produced. The CSF is not a simple 
plasma filtrate. It contains a different ionic composition than plasma. For example, chloride 
concentrations are increased in the CSF (130 mM) compared to blood (106 mM), but potassium 
ions are higher in the blood (4.3 mM) than in the CSF (2.9 mM) (21). Currently, the main 
hypothesis of our lab is that aberrant regulation of these various transporters can result in the 
overproduction of CSF seen in the communicating form of hydrocephalus. 
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On a daily basis, the CP of an adult brain can produce over 0.5 liters of CSF at about 0.3 – 0.4 mL 
per minute. This fluid will circulate “from the lateral to the third ventricle via the foramen of 
Monro, on into the fourth ventricle via the aqueduct of Sylvius, and then out of the fourth ventricle 
via the midline foramen of Magendie, and the lateral foramina of Lushka” into the cisterns and 
subarachnoid space to cushion the brain until it is then absorbed back into the bloodstream at the 
arachnoid villi (22, 23). As CSF flows throughout the brain, it has been associated with not only 
bathing the various surfaces of the brain, but also works in tandem with another system to clear 
out wastes and accumulated proteins within the brain (24). This filtering occurs via the recently 
described glymphatic system located in the brain. Previously, it was believed that the body’s 
lymphatic system did not extend into the brain region. However, in 2012, data in rodent brains 
suggests that there is, in fact, a glymphatic system used by the brain to allow for fluid-clearance 
through the influx and efflux of the CSF and interstitial fluid (ISF) via water channels throughout 
the brain called aquaporin 4 (AQP4) (24). Indeed, several neurodegenerative diseases are 
associated with decreased clearance of protein aggregates from the brain, such as amyloid-β and 
neurofibrillary tangles in AD patients. Stroke and TBI have also been associated with decreases in 
glymphatic flow and clearance (24). Up until recently, the mechanism was unknown how the brain 
is able to clear these proteins from its extracellular space. However, with the discovery of the 
glymphatic system, we now have a basic, but still incomplete, understanding of how CSF and ISF 
flow is utilized to distribute and clear metabolites, proteins, and other constituents throughout the 
brain. Proper CSF flow is necessary for the glymphatic system to function. Therefore, assuming 
CSF flow is impaired in instances of hydrocephalus, particularly non-communicating 
hydrocephalus, we can also now infer how the disorder can potentially cause a decrease in 
glymphatic flow and an increase in waste accumulation in the brain parenchyma and CSF. 
1.4 Transient Receptor Potential Vanilloid 4 
One ion channel of interest in the control of the production of CSF is a mechano-, osmo-, chemo-, 
and temperature-sensitive, non-selective cation channel called Transient Receptor Potential 
Vanilloid 4 (TRPV4) (25-27). This ion channel is ubiquitous throughout the body, but specifically 
in neurons and the apical plasma membrane of the epithelial cells lining CP (21). TRPV4 is 
associated with the influx of calcium into the CP epithelium upon activation (21). This increase in 
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intracellular calcium can stimulate several different cascade pathways in a cell type-specific 
manner. In particular, the increase in intracellular calcium can be utilized to stimulate calcium-
activated ion channels, such as potassium and chloride channels. Once activated, these channels 
can cause significant ion flux across the CP epithelium and subsequent water movement through 
AQP channels, thus allowing for the secretion or absorption of CSF into and out of the ventricles 
(13, 21, 28, 29).  
 
In many regards, TRPV4 is considered a hub protein as it has many different types of stimuli that 
can subsequently activate several different pathways within the cell. The various stimuli that have 
been reported to activate TRPV4 include physical stress, such as shear, mechanical forces and 
pressure or flow alterations, osmotic changes, such as variation in ionic composition, temperature 
changes, such as that seen in inflammation, and chemical activators, such as cytokines and 
inflammatory mediators (25-28). Our laboratory is particularly interested in TRPV4 because we 
have shown that treatment with an antagonist of this channel ameliorates hydrocephalic 
development in an animal model of the disease. 
1.5 Rat Model of Hydrocephalus 
In order to study the effects of TRPV4 and various factors on hydrocephalus, our laboratory utilizes 
an in vivo rodent model called the Wistar polycystic kidney (Wpk) rat. This model is orthologous 
to the ciliopathy Meckel-Gruber Syndrome type 3 (MKS3), a rare genetic disorder characterized 
by renal cysts and central nervous system malformations, such as occipital encephaloceles (30-33). 
The development of MKS3 in humans involves a genetic single point mutation on chromosome 5 
encoding the transmembrane protein 67 (TMEM67). An orthologous mutation in Wistar rats 
results in the Wpk rat with polycystic kidney disease (PKD) and severe, rapidly-progressing, 
communicating form of hydrocephalus in the homozygous recessive animals. These animals only 
live for about 3 weeks as their disease phenotypes progress (30, 31, 33). In terms of a reliable 
model, the homozygous Wpk rat is analogous to the congenital pediatric form of hydrocephalus. 
 
Data suggest that the mutation in TMEM67 is a gene dose-dependent hydrocephalic phenotype as 
the heterozygous Wpk rats also develop a mild, asymmetrical form of hydrocephalus (33). 
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However, this hydrocephalus does not become physically evident until about one year of age, 
about half the lifespan of a normal wild type rat, at which time the afflicted animal begins to show 
evidence of decline including failure to groom. Because the condition does not appear until later 
in life, this form of hydrocephalus is considered a slowly-progressing type similar to that seen in 
adult hydrocephalic patients. It is also of note that the heterozygous animals do not develop the 
confounding variable of PKD like that seen in the homozygous animals (33). 
 
Preliminary data from our lab suggest that treatment of hydrocephalic rats with a TRPV4 
antagonist is able to prevent enlargement of the ventricles (Figure 1.1). Head dimensions were 
measured in normal and hydrocephalic rats. We found that the hydrocephalic rats treated with the 
TRPV4 antagonist RN1734 developed head dimensions comparable to those of the wild type both 
treated and untreated with the same antagonist (Figure 1.1) (34). From this data, we believe that 
TRPV4 antagonism may be used as a pharmaceutical alternative to invasive surgery. No 
significant adverse effects have been established so far in relation to TRPV4 inhibition. Several 
TRPV4 knockout models have been developed with mild abnormalities. The majority of knockout 
mouse phenotypes are related to osmotic regulation or sensory stimulation. However, none of these 
knockouts experience severe phenotypes detrimental to the animal (35, 36). In addition, currently, 
TRPV4 channel blockers have been approved for use in clinical trials by GlaxoSmithKline to 
assess safety and efficacy in treating problems with pulmonary gas transfer and respiration in 
human congestive heart failure patients (37). Together, this implies that utilization of TRPV4 
antagonists as a treatment option may be a safe alternative with minimal adverse effects in patients. 
1.6 Choroid Plexus Cell Line 
In addition to the in vivo model, our laboratory has also performed extensive research on an in 
vitro model of CP cells. The porcine choroid plexus-Rheims (PCP-R) cell line is derived from 
primary porcine choroid plexus epithelial cells that were selected through a series of subcultivation 
steps until the viable continuous line was obtained (38). This cell line is a high resistance, barrier 
epithelium capable of mimicking the blood-CSF barrier seen in vivo (28, 38). The epithelial cells 
of the CP are interesting in that they are highly polarized, meaning important ion channels can be 
present on either the apical or basolateral sides. This polarity allows the cells to regulate the 
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composition and production of the CSF (21, 28). Much of the following research involves 
elucidating the characteristic localization of these imperative ion channels in the CP epithelium 
utilizing the PCP-R cell line. 
 
As the cells are grown as a monolayer on supported Transwell filters, we are able to alter the 
composition of the apical and basolateral media by the addition of various compounds in order to 
influence changes to the expression of TRPV4 into the epithelial membrane. Mounting the 
monolayer of cells in Ussing chambers and using electrophysiology is a technique that allows for 
the measurement of the transepithelial ion flux and cellular permeability of the PCP-R cells in 
response to experimental compounds. Specifically, an agonist for TRPV4, GSK1016790A, is 
utilized to stimulate TRPV4 activation in the cells (28). We pretreat the cells with other compounds 
that either block or activate various channels or genes thought to be involved in the TRPV4 
pathway prior to activating TRPV4 itself with its agonist. In this way, we are able to piece together 
how TRPV4 is involved in the regulation of these channels and how the various pathways can be 
utilized for future pharmacotherapies. 
1.7 Ion Channels in the Choroid Plexus 
The CP is home to many different ion channels capable of transporting a plethora of ions to and 
from the blood and CSF. While not all of these channels are believed to be modulated by TRPV4, 
many are still important to the production of CSF and maintenance of the epithelial cell. 
 
Many of these ion channels are responsible for the unique polarity seen in CP cells as specific 
channels are located on either the apical or basolateral side. For example, the Na+/K+ ATPase pump 
responsible for transporting sodium out of the cell and potassium into the cell is normally found 
on the basolateral membrane in all other tissues of the body. However, in the CP, this pump is 
found on the apical membrane and is believed to play a major role in establishing the ion gradient 
responsible for ion movement and CSF production (21).  
 
In addition to the Na+/K+ ATPase, another ion channel normally found on the basolateral 
membrane in other tissues but found on the apical membrane of the CP is the Na+/K+/2Cl- co-
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transporter NKCC1 (21). This cotransporter is responsible for moving sodium, potassium, and two 
chloride ions across the cell membrane. In particular, NKCC1 has been reported to play a major 
role in the production of CSF (7, 39). In the WNK signaling pathway, the intracellular Ste20-
Related Proline/Alanine-Rich Kinase (SPAK) and Odd-skipped-related 1 (OSR1) play an integral 
role for the regulation of various ion channels, importantly including the activation of NKCCs and 
the sodium and chloride influx co-transporter (NCC) as well as the the inhibition of the potassium 
and chloride efflux co-transporters (KCCs) (7, 40). SPAK has also been reported to be activated 
in response to increases in NF-κB binding, a transcription factor involved in the regulation of 
inflammatory pathways; this pathway has been implemented in the hypersecretion of CSF through 
the binding and phosphorylation of NKCC1 at the apical membrane, potentially linking it to 
hydrocephalus (7, 40). The multitude of related pathways through which SPAK is involved in ion 
transportation makes this kinase an important target for current ion transport studies.   
 
In all tissues studied to date, NKCC1 activation results in influx of sodium, potassium, and chloride 
into the intracellular space. However, recent studies have suggested that when ion gradients have 
reached favorable intracellular concentrations, NKCC1 can be stimulated to change direction and 
instead transport its ions out of the cell and into the ventricular space (41). This change in direction 
has been postulated to be responsible for the outward flow of water necessary for CSF production.  
Much of the regulation for this change in direction is unknown and highly controversial. However, 
in order to establish the change in the ion gradient responsible for switching NKCC1’s 
directionality, there must be other channels involved to allow ions to enter and exit the cell. Due 
to the fact that TRPV4 is known for bringing calcium into the cell, it is feasible that the channels 
involved include calcium-sensitive channels, such as potassium and chloride channels.  
 
Among the potassium channels, there are three different types of calcium-sensitive channels: the 
large or big conductance potassium channel (BK; KCa1.1)), the intermediate conductance 
potassium channel (IK; KCa3.1; KCNN4), and the three small conductance potassium channels 
(SK1, SK2, SK3; KCa2.1, 2.2, 2.3) (42). While there is currently not concrete evidence as to the 
localization of these channels, some data suggest that the BK channel as well as the KCNN4c 
isoform of the IK channel exist on the apical membrane (28, 43-46). Therefore, the secretion of 
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potassium ions from these channels into the ventricular space can result in the subsequent 
movement of water and thus play a role in the production of CSF. 
 
Among the calcium-sensitive chloride channels reported to interact with TRPV4 is the 
“transmembrane protein with unknown function 16A” (TMEM16A) (47-49). TMEM16A 
activation leads to an influx of chloride ions rather than an efflux of ions as seen in the potassium 
channels (49). Due to this influx of ions, it is unlikely that TMEM16A is directly resulting in the 
production of CSF as water would then be transported inside the cell. However, it is possible that 
TMEM16A is a regulator for CSF absorption for this very reason. It is also possible that the influx 
of chloride and subsequent increase in intracellular chloride could stimulate other ion channels, 
not dissimilar to how TRPV4 calcium influx has the potential to activate TMEM16A itself. For 
example, NKCC1, being a chloride co-transporter, could be stimulated to reverse direction of ion 
flux in response to TMEM16A’s increasing of intracellular chloride. Together, this shows how 
connected the various ion channels of the CP are and how they can potentially interact in order to 
regular CSF production and absorption. 
1.8 Inflammation and Cytokines 
Inflammation in the brain can be caused by a number of chemical and physical means, including 
neuronal injury from intracranial trauma, tumors, infection, hemorrhage, and aberrant protein 
accumulation due to insufficient clearance (5, 7, 50-54). The initiation of inflammation can occur 
when these different types of brain injury trigger the activation of microglia, the innate immune 
cells of the central nervous system (CNS). Microglia mediate immune responses and are 
responsible for the release of pro- and anti-inflammatory cytokines as well as the accumulation of 
inflammatory mediators at the site of injury (50, 51, 55).  
 
Aberrant protein resulting in increases in inflammatory mediators is common in neurodegenerative 
disease; amyloid-β plagues from irregular processing of amyloid precursor protein (APP) and 
neurofibrillary tangles, aggregates of the protein tau, are found in AD patients (50). Alpha-
synuclein deposits called Lewy bodies are hallmarks of PD and dementia with Lewy bodies (56). 
In addition to protein accumulations, physical injury to the cranium, as in TBI, results in cellular 
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stress and subsequent activation of the inflammatory immune response by astrocytes and microglia 
(51). Such inflammation can be associated with the development of hydrocephalus, with several 
of the inflammatory mediators shared among the aforementioned diseases upon distress. Among 
the pro-inflammatory cytokines upregulated in neurodegenerative states, interleukin (IL)-1β and 
tumor necrosis factor (TNF)-α are two of the most prominent. Anti-inflammatory cytokines are 
also found in hydrocephalic-associated diseases, including IL-10 and IL-4. Finally, some cytokines 
are considered “paradoxical” in that they are implicated in both pro- and anti-inflammatory effects. 
TGF-β and IL-6 have both been found to cause these conflicting effects (51, 57-62). 
 
Production of cytokines occurs when one of several Toll-like receptors (TLRs) are stimulated at 
the plasma membrane. TLRs vary between species, but most mammals are known to express a 
TLR family consisting of 10 different receptors (TLR1-TLR10) (63). Not all of these TLRs are 
stimulated by the same ligand. For example, TLR3 ligands include double-stranded RNA often 
present during viral infection (63). TLR4, however, is more often associated with pro-
inflammatory ligands such as heat-shock proteins or “danger signals” which can also stimulate 
macrophages and dendritic cells to begin pro-inflammatory cytokine secretion (63). Upon 
stimulation, TLRs can activate downstream signaling pathways to initiate cytokine production. 
Indeed, TLR4-deficient mice were shown to have decreases in inflammatory cytokine production. 
The same results were seen in mice deficient in TLR1 (63). Cytokines have also been reported to 
regulate the expression TLRs. For example, one inflammatory cytokine, macrophage migration 
inhibitory factor (MIF), is believed to increase expression of TLR4 as there was a decrease in the 
receptor in MIF-deficient mice (63). Several cytokines, including IL-1β and TNF-α, induce the 
expression of the gene encoding TLR2 in macrophages (63). Other studies have found specific 
TLRs upregulated in response to various cytokines. As an example, a leukemia cell line was treated 
with IL-6 for 6 hours resulting in an increased expression in all TLRs, but specifically a 12-fold 
increase in TLR7 (64). Therefore, it can be said that TLRs not only induce the production of 
cytokines, but cytokines can also act as ligands and activators of TLRs. 
 
In the canonical pathway, stimulation of TLRs by inflammatory mediators or cytokines, such as 
IL-1β or TNF-α, leads to the activation of the inflammatory signaling pathway NF-κB through the 
use of a MyD88-dependent signaling cascade, termed the IκB kinase (IKK) complex (65). 
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Phosphorylation of NF-κB by IKK allows the nuclear factor to be dissociated from its regulator 
protein, IκB, and transported into the nucleus, where it can begin transcription of several 
inflammatory cytokines (65, 66). Hence, NF-κB is a major contributor towards inflammation in 
the body. 
1.9 TRPV4 and Inflammatory Mediators 
Activation of TRPV4 can occur at temperatures above approximately 27˚C (27). Inflammation can 
result in an increase in temperature at the affected areas. Therefore, inflammation has the potential 
to activate TRPV4 directly and indirectly. Indeed, it has been thoroughly reported that the 
inflammatory lipid endocannabinoid anandamide (AEA) and its metabolite arachidonic acid (AA) 
are associated with activation of TRPV4 (27). AA can be further metabolized through one of three 
pathways. The first utilizes the enzymes cyclooxygeneases (COX) 1 and 2 to produce the 
proinflammatory prostaglandins, prostacyclin, and thromboxane A2 (67, 68). The second uses one 
of several lipoxygenase (LOX) enzymes to produce pro-inflammatory leukotrienes, lipoxins, and 
hydroxyeicosatetraenoic acids (HETEs) (69). Finally, cytochrome P(CYP)-450 epoxygenases 
metabolize AA into epoxyeicosatrienoic acids (EETs) (70). These metabolites of AA are also 
believed to stimulate TRPV4 activity (27, 71). In particular, EETs have most often been cited as 
the predominant activator of TRPV4 within the AA pathway (27, 51, 72, 73). However, there is 
some controversy as to which isoform of the EETs is the most responsible (74). Therefore, 
inflammation initiated through inflammatory mediators, such as AA and its metabolites, can 
activate TRPV4 and lead to downstream effects in ion flux and CSF production. While the scope 
of inflammatory factors capable of activating TRPV4 is unclear, there is potential for those 
involved with the ion channel to also play a role in neurodegenerative disease and hydrocephalus. 
1.10 Translational Potential 
Understanding one of the most common brain disorders (how it develops, how it can be contained 
or reversed, etc.) is vital for the millions of people worldwide affected by hydrocephalus. Therefore, 
developing and characterizing both in vitro and in vivo models to better this understanding of not 
only the disease, but also the molecular components, will greatly advance research going forward. 
 
23 
 
In addition to this, developing a comprehensive mechanism for how ion channels and CSF 
regulation affect and are affected by hydrocephalus and other neurological disorders can provide 
a basis for future treatment options. In particular, TRPV4 is implicated in several pathways for ion 
channel activation and also has the potential to be acted on secondarily by the immune response 
to injury and disease, making TRPV4 a target of interest in the study of hydrocephalus. 
 
For my dissertation research, I have been involved in several aspects of the studies directed toward 
understanding CSF production and developing drugs to treat hydrocephalus. Some of this work 
has been published and will form chapters of this thesis. Each of these publications have a preface 
explaining how I contributed towards the published work and the findings associated with those 
data. 
 
In Chapter 2, I will elaborate on the characterization and development of the Wpk rat 
hydrocephalic model in the published article, “Hydrocephalus in a rat model of Meckel Gruber 
syndrome with a TMEM67 mutation” (33). Chapter 3 will focus on the characterization of the 
PCP-R in vitro model. In the article “Activation of TRPV4 Stimulates Transepithelial Ion Flux in 
a Porcine Choroid Plexus Cell Line,” we elucidate the relationship between TRPV4 and calcium-
sensitive potassium channels (28). Chapter 4 encompasses the manuscript in final preparation for 
submission titled, “Cytokine and inflammatory mediator effects on hydrocephalus and TRPV4 
function in the choroid plexus.” This article focuses on how TRPV4 is affected by inflammatory 
cytokines and mediators associated with hydrocephalus as well as other neurological disorders.  
 
In addition to these manuscripts, Chapter 5 contains additional data I have obtained that have not 
yet been published but remain pertinent to my dissertation research. These data include further 
characterization of the in vivo models by showing the expression of TRPV4 and the tight junctional 
protein, claudin-1, in the rat model. I compared these images from the hydrocephalic rat to its wild 
type counterpart as well as to the hydrocephalic rat treated with the TRPV4 antagonist.  
 
The in vitro PCP-R model is also further characterized in Chapter 5 through RT-PCR with which 
the presence of additional ion channels and genes within the CP epithelia are clarified.  Data 
expounding other pathways potentially involving TRPV4 is also included, such as the WNK 
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signaling pathway and its associated ion channels. Finally, I observed whether microglia activation 
is present in adult and juvenile Wpk brain sections in order to determine the presence of 
inflammation in these animals. 
 
These data provide a better understanding for the development of hydrocephalus. They also 
illuminate the impact of the ion channel TRPV4 in the choroid plexus by its ability to modulate 
and be modulated by various ion channels and mediators. Together, this research establishes the 
connection between hydrocephalus and TRPV4, bringing the field one step closer to finding an 
efficient pharmacotherapy for the disease. 
25 
 
H
e
a
d
 d
im
e
n
s
io
n
 (
c
m
)
0
2
12
14
16
Horizontal Vertical
W
T
- 
v
e
h
ic
le
 
W
T
 -
 R
N
17
34
 -
 4
 m
g
/K
g
  
 h
yd
ro
 -
 v
e
h
ic
le
h
yd
ro
 -
 R
N
17
34
 -
 4
 m
g
/K
g
  
W
T
 -
 v
e
h
ic
le
 
W
T
 -
 R
N
17
34
 -
 4
 m
g
/K
g
  
h
yd
ro
 -
 v
e
h
ic
le
h
yd
ro
 -
 R
N
17
34
 -
 4
 m
g
/K
g
  
26
26 2613 135 54 4
*
*
 
Figure 1.1 Head measurements post-TRPV4 antagonist treatment in rats at P15.  
Wild-type (WT) and TMEM67(-/-) hydrocephalic pups were treated with RN1734, a TRPV4 
antagonist, by daily i.p. injections from day 7 to 15. Hydrocephalus caused an increase in both 
horizontal and vertical head dimensions (* = p<0.0001). This increase was inhibited by drug 
treatment. The numbers at the base of the columns are the number (n) of animals. Figure is 
unpublished data from the Blazer-Yost and Gattone laboratories.  
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 HYDROCEPHALUS IN A RAT MODEL WITH A 
TMEM67 MUTATION 
2.1 Preface 
In this journal article submitted to Scientific Reports in April of 2018 and accepted in December 
of the same year, I was named as co-author for conducting and analyzing experiments included in 
the article. Specifically, I contributed by performing hematoxylin and eosin (H&E) staining of the 
Wpk rat kidneys in wild type (WT), heterozygous (TMEM67+/-), and homozygous (TMEM67-/-) 
juveniles at birth (P0) and at the day of sacrifice (P15) to show the severity of the PKD in the 
TMEM67-/- animals compared to normal kidneys in the WT and TMEM67+/- animals (Figure 2.2e). 
I also provided the H&E staining of adult kidneys in WT and TMEM67+/- Wpk rats at P389 and 
P460 to illustrate that even in the older animals, there is no PKD phenotype in either the WT or 
TMEM67+/- animals (Figure 2.2f). These data provided important characteristics of the animal 
model. 
 
Further H&E staining I provided included the WT, TMEM67+/-, and TMEM67-/- P15 and the WT 
and TMEM67+/- P389 and P460 sections of the aqueduct of Sylvius (Figure 2.6a). These data lead 
to the conclusion that our rat model has a communicating form of hydrocephalus as no stenosis 
was observed in the aqueducts. 
 
The last of the data that I conducted included the immunofluorescence confocal images taken of 
P0 and P15 Wpk choroid plexus in the lateral ventricles of WT and TMEM67-/- animals (Figure 
2.8). In this experiment, I stained for aquaporin-1 and claudin-1 in order to determine whether the 
water channel and junctional protein were mislocalized in the affected animals. From these data, 
we were able to make the conclusion that the polarity of the CP cells is maintained in the affected 
animals as compared to the WT animals. Negative controls were also included in this figure to 
confirm the results. 
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In addition to the data included in this article, I also contributed by writing the methods for both 
the “Hematoxylin and Eosin” and “Immunofluorescence” sections. Finally, I assisted with 
reviewing and editing the manuscript multiple times during the initial writing and revision periods. 
2.2 Hydrocephalus in a rat model of Meckel Gruber syndrome with a TMEM67 mutation 
Joon W. Shim1,2,3, Paul R. Territo4, Stefanie Simpson1, John C. Watson1, Lei Jiang3, Amanda A. 
Riley4, Brian McCarthy4, Scott Persohn4, Daniel Fulkerson5 and Bonnie L. Blazer-Yost1* 
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2.3 Abstract 
Transmembrane protein 67 (TMEM67) is mutated in Meckel Gruber Syndrome type 3 (MKS3) 
resulting in a pleiotropic phenotype with hydrocephalus and renal cystic disease in both humans 
and rodent models. The precise pathogenic mechanisms remain undetermined. Herein it is reported 
for the first time that a point mutation of TMEM67 leads to a gene dose-dependent hydrocephalic 
phenotype in the Wistar polycystic kidney (Wpk) rat. Animals with TMEM67 heterozygous 
mutations manifest slowly progressing hydrocephalus, observed during the postnatal period and 
continuing into adulthood. These animals have no overt renal phenotype. The TMEM67 
homozygous mutant rats have severe ventriculomegaly as well as severe polycystic kidney disease 
and die during the neonatal period. Protein localization in choroid plexus epithelial cells indicates 
that aquaporin 1 and claudin-1 both remain normally polarized in all genotypes. The choroid 
plexus epithelial cells may have selectively enhanced permeability as evidenced by increased Na+, 
K+ and Cl- in the cerebrospinal fluid of the severely hydrocephalic animals. Collectively, these 
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results suggest that TMEM67 is required for the regulation of choroid plexus epithelial cell fluid 
and electrolyte homeostasis. The Wpk rat model, orthologous to human MKS3, provides a unique 
platform to study the development of both severe and mild hydrocephalus. 
2.4 Introduction 
Hydrocephalus may be congenital or develop as a consequence of trauma, infection, venous 
occlusion, tumors, or intracranial hemorrhage resulting in cerebrospinal fluid (CSF) 
overproduction, malabsorption, or mechanical blockage of flow. Hydrocephalus is observed in 
approximately 1 in 1000 births but may occur at any age including a poorly understood “normal 
pressure hydrocephalus” found in the elderly (1). Depending on severity and duration, 
hydrocephalus may cause developmental delay, progressive neurological decline, blindness, 
impaired motor function, urinary incontinence, dementia, or death.  
 
The classic but oversimplified definition of hydrocephalus describes two types, communicating 
and obstructive (2-3). In communicating hydrocephalus, the connections between the ventricles 
are open, but there is excess fluid resulting from an imbalance of CSF secretion, movement and/or 
absorption (4-6). Obstructive hydrocephalus results from a mechanical blockage of the circulation 
of CSF (7). Hydrocephalus is commonly treated by surgical placement of a shunt to divert the CSF 
(7) or an endoscopic third ventriculostomy (ETV) to create a channel bypassing a site of 
obstruction. More recently a growing number of infants are treated with an ETV and choroid 
plexus cauterization (8). 
 
Ciliopathies are a spectrum of genetic disorders where proteins found in the primary cilia are 
mutated. The primary cilium is a cellular appendage on the apical membrane of polarized cells that 
functions as a mechano- or chemo-receptor and also plays a role in the formation of left-right 
asymmetry during development (9). The most common of the ciliopathies is polycystic kidney 
disease (PKD). Other ciliopathies such as nephronophthisis (NPHP), Joubert syndrome (JS), 
Meckel-Gruber Syndrome (MKS), and Bardet Biedl Syndrome (BBS), all have central nervous 
system defects (10-11). The cilia in these diseases show abnormalities, including truncation, 
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elongation or diminished numbers. How different ciliary phenotypes result in functional defects 
of the nervous system remains poorly characterized.  
 
The Wpk rat, carrying a single point mutation in the transmembrane protein 67 (TMEM67), is a 
genetic model of hydrocephalus and PKD that is orthologous to human MKS type 3 (MKS3) (12-
13). TMEM67 is one of a complex of co-localized proteins that, when mutated, cause MKS or JS 
(14-17). In renal tissue, and mouse embryonic fibroblasts, TMEM67 localizes in the plasma 
membrane and in the area of the ciliary transition zone, a region between the basal body and 
axoneme. TMEM67 has been characterized as one of the proteins that serve as a “filter” controlling 
protein movement into the primary cilium (14, 18). In Wpk rats, the TMEM67-/- homozygous 
animals have renal cystic disease with severe hydrocephalus and survive for approximately three 
weeks (12). The heterozygous animals have no renal phenotype and breed normally in the first 
year. 
 
The current studies are designed to compare the genotype and phenotype of Wpk rats and extend 
the characterization of cerebral abnormalities. The hydrocephalus is a communicating form of the 
disease as evidenced by an open cerebral aqueduct of Silvius in both the homozygous and 
heterozygous genotypes. During post-natal development of the homozygous hydrocephalic 
animals, the disease becomes severe with bilateral fusion of lateral ventricles. While the 
anatomical structure and polarity of the choroid plexus epithelial cells remain intact in the 
homozygous pups, there is an altered barrier function and electrolyte transport across the choroid 
plexus epithelia. The heterozygous (TMEM67+/-) rats have midline malformations and mild 
hydrocephalus that does not appear to impair normal physiological functions until after the first 
year of life. The latter is, to our knowledge, the first description of an animal genetic model of 
slowly progressing hydrocephalus. These models are unique in that they avoid the necessity of 
intracranial injection of sclerotic or hemorrhagic agents to induce the disease. Both the 
heterozygous and homozygous rat models may be useful for detailed physiological, behavioral and 
pharmacological studies. 
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2.5 Results 
Identification of the TMEM67/MKS3 heterozygous mutation using dCAPS markers. The Wpk rat 
was previously shown to have a single C to T substitution within exon 12 of the TMEM67/MKS3 
gene that converts a proline to a leucine in the polypeptide (13). Although this mutation reduces 
the transcript level in kidney as determined by RNA gel blotting, there was little or no change in 
TMEM67/MKS3 RNA in brain tissues reported previously, (13) reducing the utility of RNA gel 
blotting as a genotyping tool for these studies. Moreover, to our knowledge, neither DNA blotting 
nor PCR methods for detecting the mutant allele had been previously developed. To overcome this 
limitation, we used a PCR-based method involving dCAPS markers (19). We designed 
mismatched primers flanking the mutation to create a cleavage site for MwoI only in the wild type 
(WT) allele (Figure 2.1a).  However, amplification of rat genomic DNA with the dCAPS primers 
generated several PCR products in addition to the 51 bp target because of related sequences in rat 
genomic DNA. Therefore, nested PCR was used to first amplify a 157 bp region containing the 
target sequence (Figure 2.1b), followed by a second amplification using the dCAPS primers 
(Figure 2.1c). After MwoI digestion, the PCR product from WT animals generates two closely 
migrating fragments just below the 30 bp marker (Figure 2.1d, TMEM67+/+; n=98). In contrast, 
the product from homozygous mutant animals was uncleaved, migrating near the 50 bp marker 
(Figure 2.1d, TMEM67-/-; n=72). Heterozygotes were identified by the presence of the 51 bp 
product as well as the MwoI digestion products (Figure 2.1d, TMEM67+/-; n=234). The dCAPS 
genotyping correlated well with the cerebral phenotypes described below. This technique provides 
the ability to unambiguously characterize the heterozygous animals for the first time and determine 
potential cerebral changes that result from a diminished TMEM67 protein expression. 
 
Neonatal development of the Wpk model. The hydrocephalus in the TMEM67-/- homozygous 
animals is severe, resulting in cranial doming (Figure 2.2a, b, d). At post-natal (P) day 17, the head 
dimensions of the homozygous animals were significantly increased over the control animals when 
measured in vertical (palate to cranial cap) or horizontal (biparietal) orientation (Figure 2.2d). The 
homozygous pups had a significantly reduced body weight at P12, P17, and P19 as compared to 
WT and died postnatally prior to weaning age (Figure 2.2a, c). The renal consequence of the 
TMEM67 mutation presented as severely cystic kidneys in the homozygous pups while both 
heterozygous and WT animals had normal kidneys (Figure 2.2e, g). These results are consistent 
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with the previous reports on the non-cystic and cystic Wpk rat model (12, 13, 20) but represent the 
first depiction a phenotype in heterozygous animals. As the animals age to adulthood, the renal 
phenotype of the heterozygous animals remains normal (Figure 2.2f). Unlike whole body and 
kidney, heart weight did not show a significant difference in the homozygous animals as compared 
with WT controls at P17 and the hematocrits were also normal (data not shown).  
 
To substantiate the initial findings and to further characterize the heterozygous animals, a second 
cohort was examined at post-natal day 15 (Figure 2.2e, g).  As in the first cohort, the homozygous 
animals showed a statistically significant decrease in body weight at P15.  There was no difference 
between the WT and heterozygous animals.  The brains and kidneys of these animals were also 
collected and weighed.  Whether the kidney weights or the brain weights were expressed as organ 
weight or as organ weight as a percentage of body weight, the homozygous pups were statistically 
increased over the other two genotypes. The WT and heterozygous animals were the same in all 
parameters (Figure 2.2g). 
 
Cerebral phenotype of the neonatal Wpk rats. To determine and compare ventricular volumes in 
the Wpk rats of all three genotypes, the pups were scanned using MRI at two postnatal time points. 
At P7-8, volumes of the lateral ventricle for WT, heterozygotes, and homozygotes were 1.5 ± 0.6, 
6.7 ± 1.8 and 71.9 ± 9.2 µl. After a further 10 days of maturation (P17-18), the respective lateral 
ventricle sizes were 2.6 ± 0.3, 16.7 ± 5.4 and 491.2 ± 61.9 µl, respectively (Figure 2.3). 
Interestingly, the fold change in lateral ventricular volume during neonatal aging (P7-8 to P17-18) 
for WT (1.7X), heterozygous (2.5X) and homozygous (6.8X) animals was gene dosage dependent 
and significantly different between genotypes.  Measurements in these young rats displayed the 
same order of magnitude as a previous report on basal cistern kaolin-injected hydrocephalus, in 
which ventricular volume was quantified in adult female rats (21). 
 
Cerebral characteristics in the TMEM67+/- rats. A sac-like protrusion was found during sectioning 
of early postnatal brains of the heterozygous animals suggesting an abnormality in the parietal to 
occipital lobe. In a coordinate, relatively caudal to the center of the brain where the pineal gland 
was seen, the heterozygous animals showed an elevated left hemisphere (V2MM; secondary visual 
cortex mediomedial area) as compared to that of sibling WT animals at P0. Interestingly, 
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homozygous rats did not show the asymmetry at this coordinate but, rather, the presence of a gap 
between two hemispheres with remnants of thrombotic membrane suggestive of venous sinus 
thrombosis (Figure 2.4a). In a more caudal coordinate where the aqueduct was present, the brains 
from the heterozygous animals retained the elevated height in the left hemisphere (ECIC; external 
cortex of the inferior colliculus) as compared to that of WT at P0 (Figure 2.4b).  
 
Primary cilia are involved in tissue patterning during development; therefore, to determine 
potential effects of ciliary defects in the brain, the ependyma was examined using scanning 
electron microscopy of the brain in a sagittal orientation. At birth (P0), mono-cilia were detected 
in WT and heterozygous animals with occasional presence of ciliary tuft in the ventricular surface. 
In the homozygous ependyma, however, the mono-cilia (primary cilia) appears markedly longer 
than those of the heterozygous or WT controls (Fig. 4c). In agreement with a previous report (12), 
at latter time points (P8 and thereafter), the ventricular surface was covered with tufts of cilia, 
which were very similar in WT and homozygous rats (data not shown). To quantify the ciliary 
phenotype of the ependyma revealed in the SEM, the cilia length was measured by 5 independent, 
blinded observers who were naïve to the experimental protocol. A representative count by one 
observer and the mean values of all the observers are shown in Figure 2.4d. The results were 
confirmed in two separate experiments using immunofluorescent images of anti-Arl13b stained 
cilia (images not shown). The results of the latter experiment were tabulated and the averages are 
compared with the measurements of the SEM experiments (Figure 2.4d). Both sets of experiments 
indicated that the cilia of TMEM67-/- was significantly longer than other genotypes. 
 
Because the midline protrusion in the heterozygous animals was not visible on the external surface 
of the skull, we assessed the forebrain part of the head including extra-axial space (EAS) that 
subsumes subdural and subarachnoid space. Strikingly, formation of hemorrhage in the 
dorsomedial surface within the EAS along the midline was detected in the heterozygous animals 
with an increase in size in dorsomedial EAS as compared to that of WT. At P1, the external 
hemorrhage in the EAS appeared as a bilateral protrusion with respect to the midline in the 
forebrain (Figure 2.5a, solid arrow). At P18, there was no residual indication of hemorrhage but a 
protrusion similar to that observed in Figure 2.4a was observed in the brains of these animals 
(Figure 2.5b, solid arrow).  
40 
 
The ventricular enlargement in the homozygous animals became progressively worse with age, 
severely compromising other brain tissue by P18, the age when the affected animals show signs 
of terminal disease and were sacrificed for humane reasons. The serial sections confirmed 
ventriculomegaly with fusion of both ventricles (n=23), whereas the heterozygous animals 
exhibited mild enlargement of the lateral ventricle (n=8) (Figure 2.5b). The asymmetric lateral 
ventricle and the midline protrusion in the heterozygous rat were observed starting at P8 until 
around P360 (n=7).  
 
Communication of CSF in the TMEM67-/- brain. To determine the type of hydrocephalus occurring 
in the Wpk rat, we examined the caudal CSF space and circumventricular organ at the midline. 
The SCO did not show a significant change at P0 (Figure 2.6a). The cerebral aqueduct remained 
open in all genotypes during neonatal development and into adulthood (Figure 2.6a).To further 
substantiate the finding of communicating hydrocephalus indicated by the open aqueducts, a dye 
extravasation study was performed on all genotypes by injecting Evans blue in the cisterna magna 
of Wpk rats at P18. Blue dye leakage suggests that there was no obstruction along the CSF 
circulation including aqueduct and ventricles in either the homozygous or heterozygous rats 
(Figure 2.6b). However, the Evans blue trait along the aqueduct and cistern of the homozygous 
brains was less intense than that of heterozygous and WT brains. Taken together, the Evans blue 
dye injection through the cisterna magna visualized in sagittal orientation supports the histological 
observation in coronal serial sections that communicating hydrocephalus is present in the 
TMEM67 homozygous mutant rats.  
 
Cerebral phenotype in adult TMEM67+/- rats. To determine if the mild hydrocephalus that is 
present in pre-weaning animals continues through adulthood, brain scans and analysis of MRIs 
were performed to compare WT and heterozygous animals at 8 months of age. There is a 
statistically significant difference in the size of lateral ventricles between the WT and heterozygous 
animals (Figure 2.7). Interestingly, the asymmetry of the ventriculomegaly in the heterozygous 
animals continues into adulthood. Eight of eight (100%) of the heterozygous (TMEM67+/-) rats 
developed ventriculomegaly at age 8 months as compared to the age-matched WT (n=10).  All 
animals were included in the analysis and there was no overlap in ventricular volume between the 
WT and heterozygous animals (Figure 2.7). 
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Choroid plexus epithelium and barrier function. The choroid plexus epithelial cells are responsible 
for the nature of the blood-choroid plexus barrier. In addition, polarization of membrane proteins 
is necessary for vectorial osmolyte transport. To further characterize these epithelial cells in the 
disease state, the polarization of relevant membrane proteins was examined. Aquaporin 1, a water 
channel present in the choroid plexus was localized primarily to the apical plasma membrane in 
plexuses derived from new-born WT and homozygous pups. This localization was maintained in 
the homozygous animals at 15 days of life (Figure 2.8a) 
Claudin 1, considered a barrier claudin, is a tight junction protein important for maintenance of 
transepithelial permeability (22, 23). Claudin 1 staining is similar in the newly born WT and 
homozygous pups but decreased in intensity after 15 days in the homozygous animals (Figure 
2.8b).  However, despite the decrease in intensity, the claudin-1 polarity to the apical junctions is 
maintained in the older pups. 
 
Taken together, the localization studies indicate that the cells are viable and that a major transport 
protein as well as a junctional complex protein are appropriately polarized, albeit, with possible 
changes in quantitative expression levels.  
 
The vascular permeability of the TMEM67 mutant brains was assayed to address changes in barrier 
function in animals with hydrocephalus (24, 25) Intracardial injection of Evans blue demonstrated 
that blue dye extravasation was significantly increased in brains from homozygous as compared 
to WT animals. Interestingly, we noted that Evans blue leakage was detected in the choroid plexus 
of the TMEM67-/- rats (arrows, Figure 2.9a). To examine leakiness of the vasculature in the 
cerebral cortex, we administered intracardial Evans blue dissolved in saline. The area of Evans 
blue dye extravasation excluding the ventricular surface was measured which eliminated the 
confounding effect of dye leakage in the ventricles including the choroid plexus. Dye leakage in 
the cerebral cortex of the homozygous rats excluding ventricles was significantly elevated 
(p=0.002; Kruskal-Wallis with Dunnett’s post hoc tests) as compared to WT animals (Figure 2.9 
a-d).  
 
Minor changes in vascular leakage and/or a change in the epithelial permeability of the blood-CSF 
barrier might be expected to have functional consequences manifested in the composition of the 
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CSF. Of the major electrolytes found in the CSF of late-stage hydrocephalic rats compared to 
control animals. Na+, K+ and Cl- are all statistically elevated in the hydrocephalic animals (Figure 
2.9e). 
2.6 Discussion 
Hydrocephalus is a serious disease that can occur at any age and can arise from a multitude of 
causes.  Regardless of cause, the main treatment is surgical intervention to divert excess CSF to 
other areas of the body and/or ablation of the choroid plexus to decrease CSF production.  
Development of pharmacological interventions has been hampered, in part, by a lack of 
physiologically relevant animal models, particularly those that demonstrate a more slowly 
progressing form of the disease and live long enough to allow a reasonable course of drug treatment. 
 
The TMEM67 homozygous rat is an orthologous model of MKS3 and demonstrates many of the 
characteristics of the human disease including severe polycystic kidney disease and brain 
abnormalities (12, 13, 20). Like the homozygous rats, the human patients with MKS die in the 
perinatal or neonatal period (10). In the course of the current studies, we made the fortuitous 
observation that the heterozygous breeders had a mild form of hydrocephalus that appears to 
adversely affect the animals at approximately one year of age when they begin to show moderate 
signs of stress like failure to groom.  Because of the difficulties in genotyping animals with a single 
nucleotide mutation, previous studies failed to distinguish WT from heterozygous animals and 
breeders were classified as heterozygous when they produced off-spring with neonatal 
hydrocephalus and grossly enlarged kidneys (12, 20). Accurate genotyping of the heterozygous 
Wpk animals by combining a nested PCR and dCAPS approach allowed us to genotype the animals 
shortly after birth and provided the ability to characterize the heterozygous animals in the neonatal 
period. Particularly important in this regard is the ability to distinguish differences in the 
ventricular volumes of all three genotypes as early as post-natal day 7-8 by MRI. 
 
Due to both the severe hydrocephalus and cystic renal disease, homozygous pups succumb to the 
disease in the first few weeks of life.  There is a statistically significant decrease in weight gain as 
early as post-natal day 12.  At post-natal day 15, the kidney and brain weights of the homozygous 
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animals are significantly increased while, interestingly, the heterozygous animals are 
indistinguishable from WT in both parameters.  In the homozygous animals, it has been reported 
that the disease results in fatality by 4-6 weeks (20). In the current studies, these animals were 
humanely sacrificed at or before post-natal day 18.  Of interest for future studies is the finding that, 
while heterozygous animals maintain a hydrocephalic state through adulthood, there is no evidence 
of cystic kidney disease in the adult animals. 
 
Both genotypes appear to express a communicating form of hydrocephalus.  This is indicated by 
the open cerebral aqueduct on Silvius in both the neonatal and adult animals.  In addition, Evan’s 
Blue injection into the cisterna magna at P18 suggests that there was no obstruction along the CSF 
circulation including aqueduct and ventricles in either the homozygous or heterozygous rats.  
These results are consistent with a previous report (26) using a mouse model of a different 
ciliopathy, BBS, where the authors also found a communicating form of hydrocephalus after 
Evan’s Blue injection. 
 
In interpreting the MRI results of the adult animals, it is important to note that Wistar rats have a 
high degree of spontaneous ventriculomegaly. In a study by Tu et al., the incidence of enlarged 
ventricles was 19% (27). In the current study, no animals were excluded from analysis and no 
increased ventricular size was detected in any of the WT adults (n=10) that were analyzed by MRI.  
In addition, there was no overlap in the size of the lateral ventricles when comparing adult WT 
and heterozygous animals of the same age. 
 
The TMEM67 gene appears to be related not only to ventricular size but also to regulation of cilia 
length and midline morphogenesis. An elongated ciliary phenotype has been reported in primary 
cilia of extra-cerebral tissues from patients with Meckel syndrome (11) and in Wpk rats (28). 
Studies of at least two other in vivo ciliopathy models of polycystic kidney disease (jck and cpk 
mice), have also reported the unusually long primary cilia in the kidney and bile duct (29, 30). In 
the ventricles, primary cilia are virtually impossible to measure after P0 because the animals 
develop tufted motile cilia which obscure the primary cilia within a day after birth. Previously 
published studies have shown that there is no difference in the tufted cilia between the WT and 
homozygous animals (12). However, the renal cilia length has been published for the WT and 
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homozygous rats (28). In the kidney, one does not have the confounding variable of tufted, motile 
cilia. Tammachote and colleagues reported a statistically significant increase in the number of cilia 
with lengths greater than 3 µM in the homozygous animals. It should be noted that in the previous 
report (28), genotyping was not done so the unaffected animals would be a mixture of WT and 
heterozygous pups. The current results are entirely consistent with the previous studies. In the 
homozygous animals, the primary cilia are statistically longer than those of the heterozygous or 
WT animals and are also longer than 3 µM. An entirely new finding is that the cilia from WT and 
heterozygous animals are not statistically different. 
 
Hemorrhage in the brain is a primary causal factor in the development of communicating 
hydrocephalus (25, 31-33). Dorsomedial hemorrhage seen at P1 in the TMEM67 heterozygous rat 
and appears to be linked to midline malformation in the current study. Heterozygous pups (n=3) 
showed dorsomedial hemorrhage in the extra-axial space adjacent to SAS. There was no evidence 
of hemorrhage after P7 and, interestingly, there was also no evidence of hemorrhage in the 
homozygous animals. The role of hemorrhage and its possible association with mild hydrocephalus 
needs further investigation. 
 
One potential cause of aberrant fluid homeostasis in ciliopathies is the mislocalization of polarized 
proteins in barrier epithelial cells responsible for electrolyte and fluid movement (34, 35). However, 
we find no evidence of mislocalization in the current studies. The choroid plexus water channel 
aquaporin 1 shows a predominately apical expression in both the WT and homozygous animals at 
birth and this polarity is maintained at P15. Likewise, claudin-1, a junctional protein important for 
maintenance of epithelial barrier function (23) shows an apical distribution, localized to the apical 
junctional complexes in both the WT and homozygous pups at birth.  At day 15, the claudin-1 is 
still localized predominately on the apical side of the epithelia of the homozygous animals, albeit 
with a decreased intensity.  
 
Thus, a junctional protein important for epithelial cell polarization, as well as a transport protein 
with a defined polarity in choroid plexus epithelia, maintain normal distributions. Despite the 
maintenance of normal cellular polarity, the Evan’s Blue studies indicate an enhanced dye leakage 
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across the choroid plexus. Taken together these findings suggest a controlled increase in 
transepithelial permeability. 
 
The endothelial cells of the choroid plexus have been characterized as a fenestrated capillary. 
Therefore, they form an area of the vasculature that is leaky to small molecular weight compounds. 
Under normal conditions it is the epithelial cells of the choroid plexus, a high resistance epithelial 
monolayer, that form the blood-CSF barrier.  Under normal conditions, polarized electrolyte 
transport across the epithelium results in CSF that contains a higher concentration of Cl- and a 
lower concentration of K+ than plasma (4, 36). Na+ concentrations are approximately equal in these 
two extracellular fluids.  It follows, therefore, that if the development of hydrocephalus in the rat 
model is due to a non-specific increase in permeability across the epithelial cell barrier, the 
resulting CSF would have a composition more similar to a plasma filtrate.  In this scenario, the Cl- 
concentration would decrease and the K+ concentration increases while the Na+ concentration 
would be relatively unchanged.  Surprisingly, this is not the case in the severely hydrocephalic 
animals where all three electrolytes are higher in the CSF compared to WT. These results further 
substantiate a controlled and specific increase in electrolyte secretion across the choroid plexus 
epithelial cells and into the CSF. 
 
From these results, the development of the hydrocephalus could be predicted to be due to the 
increased osmotic gradient, which would cause fluid accumulation in the CSF. Substantial further 
investigation is necessary to determine which transporters may be primary in this altered 
transepithelial transport. However, it is interesting to note that renal cystic development in 
ciliopathies has been shown to be primarily due to an aberrant regulation of transepithelial Cl- 
transport (37, 38). Since the transporters responsible for maintaining of K+ and Cl- gradients can 
be modulated by a variety factors including inflammatory cytokines, pressure, osmolarity, 
hormones, neuromodulators and intracellular signaling components, these proteins are important 
targets for regulating CSF production.   
 
Based on the current findings, the TMEM67 homozygous rat is a good model of MKS as it 
demonstrates encephalocele-like changes, midline malformation and renal cystic disease (13-18, 
39, 40). In addition, the characterization of the TMEM67+/- phenotype elucidates a novel and 
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potentially useful model of more slowly progressing hydrocephalus. In the first year of life, the 
heterozygous animals groom themselves, reproduce normally and care for their young. However, 
at approximately one year of age, the animals start to exhibit signs of stress. They become unkempt 
in appearance and, on occasion, we have noted that the eyes seem to bulge. By 13 months of age, 
many of the animals have to be sacrificed for humane reasons, well before the expected life span 
of WT rats (~2 years). MRIs conducted to compare WT and heterozygous animals at 8 months of 
age, when the animals are still healthy, indicated that the hydrocephalus present at P18 is 
maintained chronically over the life of the TMEM67+/- animals. These studies represent the first 
demonstration of hydrocephalus in the heterozygous Wpk rats and as such makes them unique as 
a slowly progressing hydrocephalic model. These studies also highlight the importance of further 
studies to elucidate the factors that control electrolyte transporters in the choroid plexus barrier 
epithelial cells and are likely to be important pharmaceutical targets in the control of CSF 
production. 
2.7 Methods 
Generation of a derived cleaved amplified polymorphic sequences (dCAPS) marker for the Wpk 
mutation. To detect WT and mutant alleles of the Wpk rat TMEM67 gene, a derived cleaved 
amplified polymorphic sequences (dCAPS) approach was employed (19). We located the region 
containing the point mutation in the Wpk rat in chromosome 5 (RefSeq NC_005104) and 
TMEM67 mRNA sequences (RefSeq NM_001107916) from NCBI. The C to T substitution in the 
Wpk mutant (13) occurs at nucleotide 1186 in exon 12 within the TMEM67 mRNA.  The sequence 
containing the mutation did not lie within any known restriction site, making it impossible to 
design a traditional CAPS marker. Therefore, a dCAPS approach was adopted using MwoI 
restriction enzyme since all point mutations except A to T can be converted into a marker for MwoI 
(19). The Wpk/TMEM67 dCAPS forward primer was 5’-CCTGGCTGACTTTCCCAGTG-3’ and 
reverse primer was 5’-GTATATTCCAGGTAAATATCAGCAAACACA-3’. The 3’-end of the 
dCAPS forward primer was directly 5’ to the mutation site. The reverse primer was 3’ to the point 
mutation (‘Reverse’ in Figure 2.1a) in the intron immediately following the exon containing the 
point mutation. The mismatched G at the 3’-end of the forward primer and the mismatched GC 
near the 3’-end of the reverse primer create the left- and right-hand GC dinucleotides within the 
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MwoI site after PCR. In preliminary amplifications, the dCAPs primer pair generated several 
discrete PCR products with rat genomic DNA because of the presence of closely related target 
sequences in the genome. This complication was alleviated by using nested PCR. The forward and 
reverse primers for nested PCR were 5-GCTATGAGAGAGCAGGGGAG-3’ and 5’-
AACTCCTGGCTGACTTTCCC-3’, respectively (Figure 2.1 a). Nested PCR provided a PCR 
product of 157 bp (Figure 2.1b) to use as a template for subsequent amplification with the dCAPS 
primers (Fig. 1c). Total DNA for PCR analysis was isolated from tail clips using QIAamp DNA 
Kit (Qiagen).  
 
Nested PCR was carried out in 20 μl containing 25 ng genomic DNA following the manufacturer’s 
instructions (GoTaq®Green Master Mix). Cycling conditions were: denaturation at 95°C for 2 min, 
followed by 30 cycles of denaturation at 95°C for 30 sec, annealing at 49.5°C for 15 sec, and 
extension at 72°C for 30 sec. The dCAPS PCR was performed in 20 μl reactions containing 2 μl 
of amplified products from the nested PCR with the following cycling conditions: 95°C for 5 min 
(denaturation), followed by 30 cycles at 95°C for 15 sec (denaturation), 44°C for 15 sec (annealing), 
and 72°C for 5 sec (extension). PCR products were digested with MwoI (New England Biolabs) 
in total reaction volumes of 50 μl by adding 10 μl of PCR product to 5 μl of the 10X CutSmart 
buffer (1:10 dilution) containing 5 units of MwoI (34 μl H2O, 10 μl PCR product, 5 μl 1X 
CutSmart buffer, and 1 μl MwoI). The samples were then incubated at 60°C for 1 h. Following 
digestion, the samples were separated by electrophoresis on vertical 15% polyacrylamide gels in 
1X Tris/boric acid/EDTA (TBE) buffer and visualized by staining with ethidium bromide. Two 
different size markers of 50 bp DNA ladder (New England Biolabs, NEB#B7025) and 10 bp DNA 
ladder (Invitrogen/ThermoFisher, SM1313) were used for the nested PCR, and the PCRs pre- or 
post-MwoI digestion, respectively. 
 
Animal procedures. The Wpk rats on a Wistar background were bred as previously described (12, 
13, 20). Neonatal pups (postnatal day 0 to 18; P0 to P18), both male and female were randomly 
assigned to be used based on genotype. For the adult rat radiological study, TMEM67+/- rats at the 
age of 8 months were used (n=8) as compared to the WT controls (n=10). At the time of sacrifice, 
the body weights were measured and the animals were anesthetized with an overdose of sodium 
pentobarbital (150 mg/kg body weight). Blood was collected via cardiac puncture and the carcass 
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was flushed with saline and perfused intracardially with 4% paraformaldehyde (PFA). Kidneys 
and hearts were removed and weighed. Biparietal and vertical (palate to cranial cap) head 
measurements were taken with Vernier calipers (Manostat, Merenschwand, Switzerland). In 
animals that were not perfused, the CSF was collected with 25-gauge needle through cisterna 
magna in a sagittal position and transferred to the freezer (-80 C˚) prior to electrolyte analysis.  
Rodent use and procedures conformed to the National Institutes of Health (NIH) guidelines and 
were approved by the Institutional Animal Care and Use Committees at Indiana University Purdue 
University Indianapolis and the Indiana University School of Medicine. Both male and female 
animals were used. 
 
Electrolyte analysis. CSF was collected from terminally anesthetized normal and homozygous 
pups aged 15-20 days. In the case of the hydrocephalic animals, each n was from an individual 
animal.  For the normal animals, CSF was pooled from 4-6 animals for each determination. Ionic 
composition of Na+, Cl-, and K+ was quantified and osmotic concentration [mOsM] in the CSF 
was determined. The electrolyte quantification was performed at the IU Health Pathology 
Laboratories of the Indiana University School of Medicine. 
 
Magnetic resonance imaging (MRI).  On day P7-8 and P17-18, rat pups were briefly removed from 
their litter, sedated with 5% isoflurane (balance medical oxygen) and anesthesia maintained with 
1-2% isoflurane (balance medical oxygen). Adult animals (P240 + 3 days) were lightly sedated 
with 2% isoflurane. High resolution T2-weighted (T2W) MRI images were acquired using a 3T 
clinical MRI scanner (IMAGNETOM Trio, Siemens Healthcare, Erlangen, Germany) outfitted 
with a dedicated 4 channel rat head coil and bed system (RAPID MR, Columbus, OH). Images 
were acquired using a 3D SPACE sequence with the following acquisition parameters: (TA: 
5.5min; TR: 2080ms; TE: 162ms; FS: On; Ave: 2; Flip Angle: 150; Slice Thickness 0.2mm: Matrix: 
192x192; FOV: 35mmx35mm) yielding 0.18 x 0.18 x 0.2mm resolution images. Volumes of 
interest (VOI) on lateral ventricles were determined from threshold-based image segmentation of 
native CSF contrast, and images were quantified for lateral ventricular volumes using Analyze 
12.0 (AnalyzeDirect, Overland Park, KS). 
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Histology. Rats were terminally anesthetized with sodium pentobarbital and intracardial perfusion 
was conducted with saline followed by 4% paraformaldehyde (PFA). Harvested brains and kidneys 
were immersed in 30% sucrose in PBS at 4C˚ for 2-3 days or when cryo-protected tissue has 
sunken down to the bottom of the dish. The tissue in sucrose solution was briefly washed with 
PBS and further placed in a square mold with optimal cutting temperature (O.C.T.) compound 
(Tissue-Tek) at -170 C˚ using dry ice and isopentane (Fisher Scientific), in a rectangular aluminum 
tray. Snap-frozen molds containing tissue specimen were kept at -80 C˚ until cryo-sectioning (25). 
Following the rostral-caudal axis in the rat brain atlas (41), 2 mm rostral to the bregma (bregma 
+2.0 mm) was identified during sectioning and labeled ‘start of the lateral ventricle or SLV’. The 
selection of slides for comparison among genotypes was based on the distance from the SLV. 2 
mm caudal to SLV corresponds to the bregma in controls (P18). In massively hydrocephalic 
sections, however, the volume of the brains was higher than that of controls. Therefore, serial 
sections were obtained prior/post the bregma target of interest to determine the identical 
anatomical location for the sections from control and hydrocephalic brains. Appearance of third 
ventricles, dorsal and ventral hippocampus, aqueduct, SCO, the fourth ventricle and cerebellum 
during coronal sectioning formed secondary references to the SLV in the sections from 
hydrocephalic brains as compared to the control. During cryosectioning, 20 µm thickness was 
applied at -23 C˚. Selected serial sections were stained with hematoxylin alone or hematoxylin and 
eosin. Stained sections were imaged with a light microscope (M420, Heerbrugg, Switzerland), and 
images were captured using Kodak camera (DC290, Rochester, NY). In assessing CSF circulation, 
sterile filtered 1% Evan’s Blue (4 µl/g body weight) in PBS was injected to cisterna magna using 
a 25-gauge needle at about 6 µl/sec (21). To examine barrier function within the central nervous 
system, 1% Evan’s Blue (4 µl/g body weight) in PBS was injected intracardially using a 25-gauge 
needle, prior to 4% PFA perfusion. 
 
Hematoxylin stain. Frozen sections were air dried at room temperature for 10 min. Sections were 
stained in hematoxylin solution (Surgipath 01522) for 1 min. Sections were then washed with 
ultrapure water or Milli-Q® (MQ) water for 4 min (twice), acidic alcohol solutions for 5 min, and 
MQ water for 4 min. Sections were then immersed in ammonia water (or sodium bicarbonate) 5-
6 times slowly, MQ water for 4 min, and graded ethanol (EtOH) in the following order: 80 % 
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EtOH for 4 min, 95 % EtOH for 1 min (three times), 100 % EtOH for 1 min, 100 % EtOH for 3 
min, Xylene for 5 min, and mounted with Permount medium (Fisher Scientific). 
 
Hematoxylin and eosin stain. Sections were allowed to come to room temperature then stained 
with hematoxylin (Poly Scientific #s212A) for 3 minutes. Stained sections were rinsed with 
deionized water before washing in tap water for 5 minutes. Slides were dipped in acid ethanol (1 
mL concentrated HCl + 400 mL 70% ethanol in water) 8-12 times, rinsed twice in tap water for 1 
minute each, then rinsed in deionized water for 2 minutes. Sections were then stained with eosin 
for 30-45 seconds and dehydrated with three 5 minute washes in 95% ethanol, followed by three 
5 minute washes in 100% ethanol, and finally three 15 minute washes in Xylene. Slides were then 
coverslipped with Permount mounting media (Fisher Scientific #SP15-100) and allowed to dry 
overnight. 
 
Immunofluorescence. Slides were incubated with primary antibodies diluted in blocking solution 
overnight at 4°C, rinsed, and incubated with the secondary antibodies for 1 h at room temperature. 
Primary antibodies were rabbit anti-claudin 1 or anti-aquaporin 1 (1:100 dilution; Abcam) and 
anti-Arl13b (1:100, Proteintech). The secondary antibody was Alexa Fluor dye-conjugated goat 
anti-rabbit IgG (diluted 1:1000; Invitrogen). For nuclear staining 4',6-diamidino-2-phenylindole 
(DAPI) 500 ng/ml (Sigma) was used. Confocal images were taken on a Leica TCS SP8 high speed 
multiphoton and confocal imaging system. For low magnification fluorescence micrographs, a 
Nikon 90i microscope with Spot RT cooled CCD camera was used. 
 
Scanning electron microscopy (SEM). The specimens were fixed with the appropriate aldehyde 
fixative for a minimum of 2 hours. They were then rinsed with PBS and post fixed with 1% osmium 
tetroxide in 0.1M Phosphate Buffer for 2 hours. Post fixation and rinsing with PBS, the specimens 
were dehydrated through a series of ethyl alcohols then chemically dried using HMDS 
(hexamethyldisilazane, Electron Microscopy Sciences, Fort Washington, PA). The schedule was 
as follows: 2 parts 100% ethyl alcohol/1-part HMDS for 15 minutes, 1 part 100% ethyl alcohol/2 
parts HDMS for 15 minutes, then 2 changes for 15 minutes each with 100% HDMS. After HDMS 
depletion, the specimens were allowed to air-dry in a hood overnight, mounted on aluminum stubs 
with adhesive tabs, and sputter coated for 3 minutes using a Polaron (Energy Beam Sciences, 
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Agawam, MA). The specimens were viewed on a JEOL 6390LV (Peabody, MA) scanning electron 
microscope and digital images were taken.  
 
Image Analysis. To quantify Evans blue leakage in the brain, images of coronal sections were 
analyzed using NIH ImageJ. Briefly, micrographs showing hematoxylin or H&E stained sections 
were processed through line measure function. For the assay of barrier functions, photographs with 
Evans blue extravasation were processed through sharpen, edge detection, binarization, and pixel 
count. This enabled the calculation of pictorial elements or blue dye stained areas of the brain (with 
albumin to which Evans blue binds). Serial sections with 100 µm interval involving forebrain, 
midbrain, and hindbrain from three animals per genotype were used. To quantify cilia length, 
blinded observers who did not have information on genotypes were asked to measure the cilia 
length as exemplified or indicated with arrows (Figure 2.4). Using ImageJ, the known scale bar (5 
µm) was used as an input and the line or curve measurement function was used to quantify the 
length of mono-cilia.  
 
Statistical analysis. Statistical analyses were performed using SigmaPlot (version 11, Systat 
Software Inc.) and Prism (GraphPad version 7). Normality of data distribution was tested using 
the F-test for unequal variance. Normally distributed data were analyzed using Student’s t-test and 
Tukey’s post-hoc test for pair-wise comparison after ANOVA when comparing two or three 
groups respectively. Non-normally distributed data were analyzed using the nonparametric Mann-
Whitney test and Kruskal-Wallis with Dunnett’s post hoc tests when comparing two and three data 
groups, respectively. Data were expressed as average ± standard error of the mean (S.E.) and were 
considered significant at the p ≤ 0.05 level. 
 
Data Availability. All data generated or analyzed during this study are included in this published 
article. 
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Figure 2.1. Characterization of the TMEM67 genotype in the Wpk rat. (a) Design of dCAPs 
genotyping approach. Primers for nested PCR are labeled Nested F and Nested R. MwoI 
indicates the sequence and location of the MwoI site created during PCR with the upstream 
and downstream dCAPs primers (labeled Forward and Reverse, respectively). The WT 
genomic sequence is labeled WT and the mutant sequence is labeled TMEM67-/-. The C→T 
mutation in the Wpk mutant is marked in red. (b) Polyacrylamide gel analysis of nested PCR 
products obtained from genomic DNA from (left to right) WT, heterozygous, or homozygous 
mutant rats. The expected product size was 157 bp. The left lane contains DNA length markers. 
Note that in the first lane to the left, a 50 bp DNA ladder (50 – 1350 bp) was used as a standard 
with 50 to 150 bp markers indicated (c) A polyacrylamide gel as in (b) except that the nested 
PCR products were amplified with the dCAPs primers (see a). The expected product size was 
51 bp. (d) A polyacrylamide gel as in (c) except that the dCAPs PCR products were digested 
with MwoI prior to electrophoresis. MwoI digestion of the dCAPS product from the WT allele 
is expected to produce two unresolved bands migrating slightly faster than the 30 bp marker. 
MwoI is not expected to cleave the dCAPs product from the mutant allele.  Note that in the 
first lane from the left of both gels(c and d), a 10 bp DNA ladder (10-150) was used as a 
standard with the 20 to 50 bp markers indicated. 
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b) 
Figure 2.1 Characterization of the TMEM67 genotype in the Wpk rat. 
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Figure 2.2. Correlation of phenotypic and genotypic characteristics in the Wpk rat. (a) 
TMEM67-/- Wpk rat displaying a dome-shaped head with reduced body size compared to a WT 
littermate at P15. (b) Typical cranial doming at P17 in the Wpk homozygous rat as compared 
with a sibling WT animal. (c) Comparison of body weights of WT and TMEM67-/- rats from 
postnatal day 0 to 21 (P0-P21). The TMEM67-/- mutants had a significantly reduced body 
weight at P12 (p=0.012), P17 (p=0.015), and P19 (p=0.01) as compared to WT. The 
homozygous animals were humanely sacrificed at day 19. (d) Measurement of head sizes of 
WT and homozygous mutant rats at P17. Head sizes in the homozygous animals were 
significantly increased over the control animals when measured in vertical (palate to cranial 
cap) (p=0.006) or horizontal (biparietal) orientation (p=0.007). Numbers in parentheses at the 
base of the columns indicate the number of animals measured. (e) Representative renal 
phenotypes of the WT, TMEM67+/- and TMEM67-/- rats at P0 (hematoxylin stain) and P15 
(hematoxylin and eosin stain). (f) Representative adult renal phenotypes of the WT and 
TMEM67+/- and TMEM67-/- rats at P389 and P460 (hematoxylin and eosin stain). (g) Body 
weight, kidney weight, brain weight, and related organ weight as a percentage of body weight.  
At the time of sacrifice (P15), body weight and organ weight were determined and the organ 
weight as a percentage of the total body weight was calculated. The numbers of animals 
analyzed are indicated on the graphs. Scale bars, 1 mm (b, e-f). Single (*), double (**), triple 
(***), and quadruple (****) asterisks denote p<0.05, p<0.01, p<0.005, and p<0.0001, 
respectively.  
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Figure 2.2 Correlation of phenotypic and genotypic characteristics in the Wpk rat. 
a) b) 
c)
) 
d) 
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Figure 2.2 continued 
e) f) 
g) 
58 
 
  
Figure 2.3. Magnetic Resonance Imaging (MRI) of the three genotypes of the pre-weaning 
Wpk rat model with TMEM67 mutations. (a) Head scan of Wpk rats at P7-8 in coronal, sagittal, 
and transverse orientation with 3 dimensional reconstructions of lateral ventricle (LV; yellow). 
(b) Head scan of Wpk rats at P17-18 in coronal, sagittal, and transverse orientation with 3 
dimensional reconstructions of the LV (yellow). A bar graph summarizing the quantitative data 
of the lateral ventricles per genotype is shown in the lower right corner. Note that the 
heterozygous animals (middle) show intermediate size in LV volume. n= 4 to 6 per genotype. 
Asterisks denote *, p<0.05, **, p<0.01, and ***, p<0.001, respectively. 
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Figure 2.3 MRI of the three genotypes of juvenile Wpk rat model with TMEM67 mutations. 
a) 
b) 
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Figure 2.4. Midline malformation and ciliary phenotype at birth in the TMEM67+/- rats.  (a) 
Twenty µm (thickness) sections of dorsal cerebral cortex along the midline in the hindbrain. 
Note that a sac-like protrusion (double arrowheads) is found in the left hemisphere of 
TMEM67+/-. At P0 a wide gap is detected between two hemispheres in TMEM67-/- as compared 
to WT. Red arrows indicate usual location of pineal gland. In TMEM67-/-, a bloody membrane 
was observed. The single arrowhead indicates the subcommissural organ (SCO). (b) A sac-like 
protrusion in the occipital lobe of TMEM67+/- (double arrowheads) as compared with WT at 
P0. Aq denotes aqueduct. Note that aqueduct is open in all genotypes at birth. n=3 per genotype 
(a representative section per genotype is shown in a-b; hematoxylin and eosin stain). (c) 
Scanning electron micrographs displaying primary cilia on the striatal side of the ependyma in 
WT, TMEM67+/- and TMEM67-/- at P0. (d) 5 blinded observers measured cilia length as 
indicated with arrows. The scattered plot of the representative measurement by an observer 
(left), the scattered plot of the combined measurement by five observers (middle), and the bar 
graph showing the combined measurement of the SEM and IF using anti-Arl13b staining of 
cilia (not shown) are presented in the lower panel. Asterisk denotes *, p<0.05 (as compared to 
WT and TMEM67+/-, respectively). Two animals per genotype.  Scale bars, 1 mm (a-b), 2 µm 
(c), and 5 µm (d) 
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Figure 2.4 Midline malformation and ciliary phenotype at birth in the TMEM67+/- rats. 
b) 
a) 
c) 
d) 
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Figure 2.5. Hemorrhage at birth and neonatal ventriculomegaly. (a) Hemorrhage in the 
TMEM67 heterozygous mutant brains at birth. The left panel demonstrates a representative 
serial section of a WT (TMEM67+/+) rat from the forebrain (sincipital) to hindbrain (occipital) 
at postnatal day 1 (P1). The subsequent three panels show three different animals with 
TMEM67+/- alleles exhibiting hemorrhage (solid arrows) adjacent to the venous sinus within 
extra-axial space adjacent to the subarachnoid space at P1. Similar results were obtained for n 
= 3 animals per genotype. (b) Representative cerebral phenotype of the TMEM67+/+, 
TMEM67+/-, and TMEM67-/- animals at P18, respectively. Note that mild ventriculomegaly 
was observed in the TMEM67+/- (n=8; 4 left enlarged, 2 right enlarged, 2 both sides) while 
bilateral dilation with fusion of lateral ventricles was seen in the TMEM67-/- rats (n=23). Arrow 
indicates a protrusion on the dorsomedial surface of the cerebral cortex in the TMEM67+/- rat. 
Scale bars, 1 mm (a-b) 
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Figure 2.5 Hemorrhage at birth and neonatal ventriculomegaly. 
a) 
b) 
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Figure 2.6. Communicating hydrocephalus (a) Representative depictions of the aqueducts of 
the TMEM67+/+, TMEM67+/-, and TMEM67-/- rats at P0, P8 and P15. Note that the aqueduct 
is open (arrow with “aq”) in TMEM67-/-. Approximate coordinates from the bregma are 
indicated based on the rat brain atlas. The images are representative of n = 3 animals of each 
genotype and age. (b) Sagittal sections injected with Evans Blue to determine continuity 
(communication) or discontinuity (obstruction) of the CSF flow. Dye leakage along the CSF 
circulation including lateral ventricle, third ventricle, aqueduct and fourth ventricle was 
visualized by the cisterna magna injection of Evans blue in TMEM67+/+, TMEM67+/-, and 
TMEM67-/- rats at P18. 3V and aq. denote third ventricle and aqueduct, respectively. Scale 
bars, 250 µm (a) and 1 mm (b). The images are representative of n = 3 at each genotype 
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Figure 2.6 Communicating hydrocephalus.   
a) 
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Figure 2.6 continued 
   b) 
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Figure 2.7 MRI of  WT and TMEM67+/- Wpk rats at 8 months of age. 
Magnetic Resonance Imaging (MRI) of the WT and heterozygous (TMEM67+/-) Wpk rats at 8 
months of age.  Head scan of Wpk rats at P240 + 3 days of age in coronal, sagittal, and transverse 
orientation with 3 dimensional reconstructions of lateral ventricle (LV; yellow).  A bar graph with 
scattered dots summarizing the quantitative data of the lateral ventricles per genotype is shown in 
the third panel. Numbers of animals scanned are indicated at the bottom of each column.  Double 
asterisks (**) denote p<0.01.  
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Figure 2.8. Immunofluorescence of membrane proteins in the Wpk choroid plexus.  Brain 
tissue was sectioned at 20 µm and incubated with primary antibody for the water channel, 
aquaporin 1, or the tight junction protein, claudin-1 (1:100 antibody dilutions). Protein 
expression is shown in WT and hydrocephalic rats at birth (P0) and P15. DAPI staining allows 
for visualization of nuclei.  Negative (-) controls were incubated with secondary antibodies 
(1:1000 dilution, AlexaFluor goat anti-rabbit IgG). Images were taken on a Leica TCS SP8 
(upright high-speed multiphoton and confocal imaging system) at 20x magnification. Scale 
bars = 50 µm. These images represent an n of at least 3 for each genotype and age. 
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Figure 2.8 Immunofluorescence of membrane proteins in the Wpk CP.  
b) 
a) 
70 
 
  
Figure 2.9. Evans blue leakage in the brain after intracardial injection of the dye.  (a) 
Representative coronal sections displaying Evans blue leakage in all three genotypes of the 
Wpk rat. Arrows indicate blue dye leakage in the choroid plexus in the lateral ventricles of a 
TMEM67-/- brain. The images are representative of n = 3 at each genotype.  (b) Magnified 
image of Evans blue leakage in the cerebral cortex, from dashed rectangles shown in a.  (c) 
Binary image of Evans blue positive pixels quantified in the cerebral cortex obtained from b.(d) 
Box plot exhibiting statistical analysis of Evans blue leakage along the vasculature of the 
cerebral cortex as exemplified on images in c. Note that Evans blue binds to albumin. Evans 
blue injection indicates a trend towards a dose-dependent increase of the dye extravasation in 
the cerebral vessels. Serial sections (n=21-29) from three animals per genotype were used. AU, 
arbitrary unit. Asterisks denote *, p<0.05. Scale bars, 10 µm (a) and 1 mm (b). (e) Ionic 
composition of the CSF from TMEM67 rats: Bar graphs demonstrating an osmotic 
concentration in milliosmolar (mOsM) of sodium (Na+), chloride (Cl-), and potassium (K+) in 
the CSF of WT and TMEM67-/- rats, postnatal day 15-20. Each bar represents 6 determinations.  
In the case of the homozygous animals, each determination was from the CSF of a single 
individual.  For the normal animals, CSF from 4-6 individuals was pooled to obtain sufficient 
material for each determination. Statistical significance from the left to the right. p=0.0103 
(CSF Na+); p=0.0013 (CSF Cl-); p=0.041 (CSF K+) by unpaired t test. Single and double 
asterisks denote p<0.05 and p<0.01, respectively. Scale bars, 1 mm (a) and 500 µm (b) 
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Figure 2.9 Ventricular Evans blue leakage and CSF ionic composition from TMEM67 rats.   
a) 
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Figure 2.9 continued 
  
b) d)
) 
c) 
e) 
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 ACTIVATION OF TRPV4 STIMULATES ION FLUX IN 
PCP-R CELLS 
3.1 Preface 
The following journal article, of which I am co-first author, was submitted to the American Journal 
of Physiology: Cell Physiology in December of 2017 and accepted in May of 2018. In this article, 
I contributed by conducting the electrophysiology experiments with the inhibitor of two of the 
three IK isoforms, TRAM34 (Figures 10-11). For this experiment, I tested two different 
concentrations of TRAM34 in order to determine whether IK was necessary for TRPV4-mediated 
ion flux and whether the IK channel was the TRAM34-sensitive or -insensitive form. Higher 
concentrations of TRAM34 showed that our cells contained the TRAM34-insensitive isoform. 
Additional data I provided for this article included the immunofluorescence experiments on the 
PCP-R cells untreated and treated with the TRPV4 agonist, GSK1016790A (Figure 6). These 
images show the protein claudin-1 in the junctional complexes of the cells. From this, we were 
able to conclude that the cell line not only grows as a monolayer, but also that the junctional 
complexes are not affected by the activation of TRPV4 via its agonist. Negative controls were 
included to further confirm our conclusions.  
 
Further contributions I provided included performing statistical analysis on all electrophysiology 
experiments. This analysis involved running Student’s t-tests on all data points compared to either 
the experimental group’s control or another experimental group within the same data set. The data 
point was deemed significant if the p < 0.02. 
 
Finally, I was involved in the formatting and revisions of this article. In regard to formatting, I 
designed and formatted the immunofluorescence and RT-PCR figures and formatted all 
electrophysiology figures published. I also assisted with the design of the CP epithelia diagram 
(Figure 12). Furthermore, during the revision process, I drafted and revised answers to reviewer 
comments and questions as well as revised the manuscript in accordance with reviewer suggestions. 
I was also thoroughly involved in reviewing and editing the manuscript in preparation for 
submission and publication. 
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3.3 Abstract 
The choroid plexus (CP) epithelium plays a major role in the production of cerebrospinal fluid 
(CSF).  A polarized cell line, the porcine choroid plexus – Riems (PCP-R) line, that exhibits many 
of the characteristics of the native epithelium, was used to study the effect of activation of the 
transient receptor potential vanilloid 4 (TRPV4) cation channel found in the PCP-R cells as well 
as in the native epithelium. Ussing-style electrophysiological experiments showed that activation 
of TRPV4 with a specific agonist, GSK 1016790A, resulted in an immediate increase in both 
transepithelial ion flux and conductance.  These changes were inhibited by either of two distinct 
antagonists, HC067047 or RN1734.  The change in conductance was reversible and did not involve 
disruption of epithelial junctional complexes.  Activation of TRPV4 results in Ca2+ influx, 
therefore, we examined whether the electrophysiological changes were the result of secondary 
activation of Ca2+-sensitive channels. PCP-R cells contain two Ca2+-activated K+ channels, the 
small conductance (SK) 2 and the intermediate conductance (IK) channels.  Based on inhibitor 
studies, the former is not involved in the TRPV4-mediated electrophysiological changes while one 
of the three isoforms of the IK channel (KCNN4c) may play a role in the apical secretion of K+.  
Blocking the activity of this IK isoform with TRAM34 inhibited the TRPV4-mediated change in 
net transepithelial ion flux and the increased conductance.  These studies implicate TRPV4 as a 
hub protein in the control of CSF production through stimulation by multiple effectors resulting in 
transepithelial ion and subsequent water movement.  
3.4 Introduction 
The choroid plexus (CP), formed by a tufted capillary surrounded by an epithelial monolayer, is 
thought to be responsible for the majority of cerebrospinal fluid (CSF) production.  CSF cushions 
and protects the brain, substantially reducing the effective weight of the organ.  CSF also serves 
as a medium to deliver nutrients, effectors and immune modulators as well as to remove toxins 
including -amyloid (6, 22, 27, 36).  In addition, CSF contributes to more subtle functions that are 
dependent on minor changes in electrolyte composition such as modulating sleep/wake cycles and 
neuronal excitability (10).   
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The CP is among the most secretory of the organ systems, with approximately 2 grams of tissue 
producing in excess of 0.5 liters of CSF per day in an adult human (7, 22, 34).  The capillary bed 
that serves as the source of the major components of the CSF is lined with a fenestrated 
endothelium, therefore, producing a plasma filtrate based primarily on molecular size.  The CP 
epithelium that surrounds the capillaries forms the blood-CSF barrier and is the basis for the 
selectivity that is responsible for the unique composition of the CSF by the regulated movement 
of electrolytes and water (7, 22, 34).   Notably, in addition to a pH differential in which CSF is 
slightly more acidic (pH 7.27) compared to the interstitial fluid (pH 7.46), there are differences in 
electrolyte composition between the CSF and the plasma (22).  Transporters and regulatory 
proteins present in the CP epithelial cells are responsible for creating and maintaining these crucial 
compositional differences.  As recently reviewed (22), the major electrolyte transporters and 
aquaporins present in the CP have been elucidated, and their polarization within the epithelial 
membranes is well established. Other, less well-documented transporters remain to be identified.  
The effectors that control the expression and activation of these CP transport proteins remain 
largely unknown.  Because the composition and volume of the CSF is not static but varies on a 
diurnal basis (10), understanding the complex mechanisms controlling the production of CSF is 
crucial for understanding critical brain functions in both health and disease. 
 
Transient receptor potential vanilloid 4 (TRPV4) is one member of a family of mechano- and 
osmotic-sensitive channels found in multiple cell types, including the CP (16, 21, 33). When 
activated, TRPV4 acts as a non-specific cation channel that allows the influx of Ca2+ into cells.  In 
several tissues, TRPV4 serves as a hub protein that coordinates multiple internal and external 
signals with the activation of electrolyte and water channels in a tissue-specific manner (9).   
TRPV4 has been shown to have direct effects on transport proteins in the brain including 
aquaporin-4 in astrocytes (5), and the Ca2+-activated Cl- channel, TMEM16A, in primary cultures 
of CP cells (30). In the hippocampus, TRPV4 was elevated 8 hours after traumatic brain injury 
and the increased expression was dependent on NKCC1 (18), a co-transporter which is also found 
in the apical membrane of native CP epithelia (35).  Calcium influx through TRPV4 has also been 
shown to stimulate Ca2+-sensitive K+ channels in a tissue-specific manner. Ca2+-sensitive K+ 
channels fall into three categories:  BK (big conductance; KCa1.1); IK (intermediate conductance; 
KCa3.1; KCNN4); or SK1, SK2, SK3 (small conductance; KCa 2.1, 2.2, 2.3) channels (28). In 
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endothelial cells of smaller resistance arteries and arterioles, low intraluminal pressure stimulates 
TRPV4 causing localized Ca2+ sparkletts which activate IK channels and reduce arteriole tone (2).  
In these resistance arteries, activation of the TRPV4 did not stimulate SK channels although the 
SK channel KCa2.3 is present in the endothelial cells.  In freshly isolated cerebral myocytes, there 
are indications that TRPV4 forms a Ca2+ signaling complex with ryanodine receptors and BK 
channels that elicits smooth muscle hyper-polarization and arterial dilation (11). TRPV4 activation 
also resulted in the secondary activation of the BK channel in a high resistance mammary epithelial 
cell line (23). TRPV4 has been identified on the apical membrane of native CP epithelia (24, 30) 
and in primary CP cell lines (20, 30). 
 
The complexity of the CP in vivo makes studying the regulation of electrolyte transporters 
challenging.  Unfortunately, most in vitro primary cultures of CP epithelial cells exhibit a very low 
transepithelial electrical resistance (TER) that is inconsistent with the barrier function of these 
epithelia in vivo.  In addition, a low transepithelial resistance poses technical difficulties when 
measuring permeability changes that may be part of an effector response.   Continuous cell lines 
recently established in one of our laboratories (H.S. and C.S.) are, to our knowledge, the only lines 
described that exhibit a moderate to high TER (25, 26).  The porcine choroid plexus – Riems (PCP-
R) cell line expresses tight junction components, including claudin-1, claudin-3, ZO-1 and 
occludin, and develops a high transepithelial resistance when grown on permeable supports 
indicating the formation of a barrier epithelium (25).  In the current studies, the PCP-R line was 
used to examine the physiological effects of TRPV4 stimulation on the permeability of the 
epithelial monolayer and on activation on electrogenic transepithelial ion flux. 
3.5 Materials and Methods 
Cell Culture: The PCP-R cell line was derived from primary cultures of porcine choroid plexus 
(25).  PCP-R cells were grown in DMEM containing 4.5 g /L glucose, 3.7 g/L NaHCO3, 24 mM 
HEPES, 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 5 µg/ml insulin. 
Cells were grown in a 75 cm2 flask until confluent (typically 7-10 days). For electrophysiology 
experiments, cells were trypsinized and  seeded onto a permeable, 0.4 µm pore diameter, filter 
support (EMD Millipore, Billerica, MA) at 50% confluent density in PCP-R media  and placed 
82 
 
inside a 6-well plate (Corning, Corning, NY). The bottom of each well was bathed in 2 ml of PCP-
R media, and 1.5 ml of the media containing cells was placed on the top of the filter. PCP-R media 
was replaced thrice weekly. 
 
Electrophysiology: For electrophysiological analyses, PCP-R cells were cultured on 6-well, 
Transwell filters for 9-12 days. Ussing-style electrophysiological techniques were used to monitor 
TER/conductance as well as changes in electrogenic transepithelial ion flux. Filters were excised, 
mounted in Ussing chambers, and connected to a DVC-1000 Voltage/Current Clamp (World 
Precision Instruments) with voltage and current electrodes on either side of the membrane. Each 
half of the chamber contains a tapered fluid compartment with fittings for voltage electrodes (close 
to the epithelial membrane) and current electrodes (at the opposite end of the chamber). Each fluid 
chamber was water jacketed to maintain a constant temperature (37oC). The cells were bathed in 
serum-free media. Media were circulated in the chambers and oxygenated by means of a 5% 
CO2/O2 gas lift. The spontaneous transepithelial potential difference was measured and clamped 
to zero, and the resultant short-circuit current (SCC) was monitored continuously as a 
measurement of net transepithelial ion flux. As per convention, a positive deflection in the SCC is 
either anion secretion (from blood to CSF) or cation absorption (CSF to blood) and a negative 
deflection indicates the opposite. TER is recorded every 200 seconds throughout each experiment 
by applying a 2 mV pulse and using the resulting deflection in the SCC to calculate the TER and 
conductance by Ohm’s law. Cultures that showed basal TERs of less than 500 cm2 were not 
used.   Conductances were also calculated from the change in SCC during the voltages pulses as 
I/V.  In all cases, the graphs shown in each panel represent a series of control and experimental 
cultures that were grown and analyzed in parallel. 
 
Immunostaining: PCP-R cells were grown to confluency on Transwell filters (9-12 days).  Cells 
were treated with diluent or the TRPV4 agonist GSK101679A for 10 minutes and then 
immediately fixed with 4% paraformaldehyde in PBS. For immunohistochemistry, the fixed cells 
were washed and incubated overnight with anti-claudin-1 primary antibody (Abcam ab15098; 
1:200 dilution) diluted in blocking solution (PBS, 1% goat serum, 1% BSA, 0.1% sodium azide) 
at 4°C. The cells were then washed and incubated with secondary antibody. The secondary 
antibody was Alexa Fluor dye-conjugated goat anti-rabbit (Jackson ImmunoResearch 111-545-
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144, 1:1000 dilution in blocking solution). For nuclear staining DAPI (500 ng/ml; Sigma D9542) 
was used. Confocal images were taken on a Leica TCS SP8 (upright high-speed multiphoton and 
confocal imaging system).  
 
RT-PCR: PCP-R cells were grown as a monolayer in a 75 cm2 flask in PCP-R media until confluent. 
Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany), according to the 
manufacturer’s supplementary protocol for animal cells grown in a monolayer. 5 µg of total RNA 
was transcribed to cDNA using the Superscript IV First-Strand Synthesis System (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s protocol using both random hexamers and oligo-
dT primers. Specific primers were designed using Primer3Plus according to mRNA sequences 
obtained from Ensembl and verified using the NCBI database. cDNA was then used for PCR 
utilizing GoTaq Green Master Mix (Promega, Madison, WI) and 10 µM forward and reverse 
primers (IDT, Coralville, IA) (Table 3.1) and the products separated on a gradient agarose gel to 
determine optimum annealing temperatures. A second PCR was carried out using only optimum 
annealing temperatures for each primer pair. Electrophoresis was carried out on a 1.5% agarose 
gel stained with ethidium bromide utilizing flanking 1 kb and 100 bp ladders and visualized under 
UV light using a ChemiDoc XRS imager (Bio-Rad, Hercules, CA). The primers used are shown 
in Table 3.1.  
 
Statistics: All results shown are displayed as mean ± S.E.M. for the number of experiments 
indicated on the graphs. Indicated plot points on all figures were compared using Two-tailed 
Students t-test. P-values less than 0.02 were considered significant. All statistical analyses were 
performed using SigmaPlot 13.0.  
3.6 Results 
The PCP-R cell line develops a high resistance monolayer when grown on permeable supports 
with optimal resistances occurring 9-12 days post seeding (Figure 3.1). Addition of the TRPV4 
agonist GSK1016790A to PCP-R cells causes an increase in transepithelial conductance indicating 
an increased permeability across the epithelial monolayer (Figure 3.2, top).  Concurrently with the 
initiation of the conductance change is a stimulation of short circuit current (SCC) indicating net 
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electrogenic transepithelial ion flux composed of anion absorption (CSF to blood) and/or cation 
secretion (blood to CSF) (Figure 3.2, bottom).  Although the conductance remains elevated, the 
net electrolyte flux returns to a level that is statistically equal to the basal level within 20-30 
minutes after agonist addition.  A 10 minute pre-treatment with either of two structurally unrelated 
TRPV4 antagonists, HC067047 or RN1734, completely blocked the increased permeability of the 
monolayer as well as the electrogenic ion flux (Figure 3.2). To determine the maximal 
concentration of the agonist which did not result in an irreversible change in conductance and ion 
flux, a dose response was performed using concentrations of 0.1, 1, 3, 5, and 10 nM GSK1016790A 
(Figure 3.3). When the TER of the epithelial monolayer falls below 100 Ω*cm2 or the conductance 
rises higher than 10 mS/cm2 it is observed that the TER will continue to fall to unmeasureable 
levels and the experiment using this culture has to be discarded (data not shown). 
 
A limited dose response was also performed for the TRPV4 antagonist RN1734 at concentrations 
of 5, 25, and 50 µM in order to determine the maximal inhibitory concentration (Figure 3.4). 
Interestingly, the agonist-induced conductance responses are immediately reversible upon the 
addition of a TRPV4 antagonist.  This reversal is accompanied by a statistically significant change 
in the electrogenic flux (Figure 3.5). 
 
To visualize how the TRPV4 agonist was affecting the junctional complexes, PCP-R cells grown 
on Transwell filter supports were treated with GSK1016790A or diluent for 10 minutes before 
fixation and staining with anti-claudin-1 antibody (Figure 3.6).  During the incubations, the Ca2+ 
concentration was maintained by the use of serum-free media because changes in extracellular 
Ca2+ have profound effects on tight junctions and epithelial conductance (13,19).  The untreated, 
agonist treated, and negative control (no primary antibody) cells were grown in the same 6-well 
Transwell plate and were treated, fixed, stained and imaged in parallel.   No obvious difference 
was observed between the junctional complexes in any of the monolayers examined; rather all 
junctional complexes remained intact. 
 
Stimulation of TRPV4 causes an influx of Ca2+ which is postulated to secondarily stimulate Ca2+-
activated channels.  Therefore primers were designed to determine the presence of Ca2+-activated 
K+ channels in the PCP-R cell line.  When negative results were obtained, a second primer pair 
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was designed to confirm the results (Table 3.1).  The only Ca2+-sensitive K+ channels found in the 
PCP-R cell line were the intermediate conductance (IK; KCa3.1) and the small conductance (SK) 
2 channels (Figure 3.7).    As expected, TRPV4 is endogenously expressed in the cell line (Figure 
3.7). 
 
The RT-PCR results were followed by electrophysiological experiments. As expected from the 
PCR results, iberiotoxin, an inhibitor of big conductance potassium channels (BK; KCa1.1) had no 
effect on the TRPV4-stimulated conductance change or transepithelial ion flux (Figure 3.8).  
Unexpectedly, apamin, a pan-SK channel blocker, was also without effect on TRPV4-mediated 
ion flux or conductance changes (Figure 3.9).  A similar lack of effect on either 
electrophysiological parameter was noted after pre-incubation with the more SK2-specific 
inhibitors tamapin, Lei-Dab, or scyllatoxin (data not shown). 
 
Pre-treatment with low dose (1 M) TRAM 34, an inhibitor of two of the three isoforms of IK, 
also termed Kcnn4, had no effect on the subsequent response to TRPV4 agonist. However, 
increasing the TRAM 34 concentration to 50 M resulted in an inhibition of both the increased 
conductance and short-circuit current (Figure 3.10).   If a moderately high dose of TRAM 34 (25 
M) was added to the apical bathing media during the pre-incubation, the response to the TRPV4 
agonist was completely inhibited; conversely if the same concentration was added only to the 
media bathing the serosal face of the tissue, there was a reduced inhibition of the ion flux 
accompanied by a substantial, but not complete, inhibition of the increased conductance (Figure 
3.11). 
3.7 Discussion 
Choroid plexus cell line models should be expected to have a phenotype characteristic of epithelia 
that maintain controlled movement of electrolytes and fluid.  In the initial description of the PCP-
R cell line, the cultures developed a transepithelial resistance of 300-600 cm2 after 6 days of 
culture on permeable supports depending on seeding density (25).  In the current studies, additional 
days in culture resulted in monolayers that exhibited even tighter epithelia, more suitable for 
electrophysiological experiments.  
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In preliminary studies, TRPV4 antagonists decrease hydrocephalic development in a genetic rat 
model of the disease suggesting a role for TRPV4 in CSF secretion (8). As in the native CP (33), 
the PCP-R cells contain TRPV4 which can be activated by a specific TRPV4 agonist.  The 
electrophysiological changes elicited by the TRPV4 agonist are inhibited by two structurally 
distinct and specific antagonists which underscores the specificity of the response.   
 
The rapid and substantial increase in transepithelial conductance elicited in response to the TRPV4 
agonist was unexpected and indicates a large change in transcellular permeability. The 
conductance plateaus at a high level indicating that the permeability remains increased even though 
the electrogenic ion flux returns toward basal levels by 20-25 minutes.  Similar large conductance 
changes have previously been described in colonic epithelia, another epithelium capable of large 
secretory fluxes, after stimulation with prostaglandins (15).  In the PCP-R cells, both the increased 
permeability and stimulated ion flux are immediately reversible by TRPV4 antagonists even after 
the initiation of a response. 
 
TRPV4 has been previously reported to regulate the integrity of the blood-CSF barrier (20). 
However, these studies are difficult to compare to the current experiments because the starting 
resistances of the primary cultures used were low (50-70 .cm2) and treatment with 10 nM 
GSK1016970A caused a disintegration of the cell junctions within 10-20 minutes.  Activation of 
TRPV4 by the phorbol ester 4-PDD (4-phorbol-12,13-didecanoate) also caused a decrease in 
transepithelial resistance (increased conductance) in a mammary epithelial cell line similar to the 
change seen in the PCP-R cells (23).  In the latter phase of mammary cell response there was down-
regulation of junctional claudins and frequent large breaks in the tight junction strands.  
 
A dose response using the TRPV4 agonist GSK1016790A in the PCP-R cell line indicated that 
while 5 and 10 nM elicited stronger responses, treatment of PCP-R cells with 3 nM GSK1016970A 
caused no overt changes in the cell junctions and did not cause an irreversible disruption of the 
epithelial structure in confluent monolayers. To mimic a physiologically relevant response, 3 nM 
agonist was used in the majority of the experiments. 
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A dose response was performed using the TRPV4 antagonist RN1734, at concentrations of 5, 25 
and 50 µM, clearly indicating that while concentrations of both 25 and 50 µM caused complete 
inhibition of the change in conductance, 50 µM had the more complete inhibition of the change in 
SCC with no adverse effects on cellular viability as measured by TER (conductance).  
 
Claudin-1, endogenously present in both native CP (12, 14, 29) and the PCP-R cell line (25 and 
Figure 3.2), is considered a barrier claudin important for maintenance of transepithelial 
permeability (14). The immunolocalization of claudin-1 did not change after stimulation with 
GSK1016970A, a finding which is consistent with the rapid reversal of the TRPV4 agonist-
mediated response by antagonist. Both findings suggest that, under our experimental conditions, 
the junctional complexes are not irreparably broken. 
 
Taken together, our results are consistent with a change in transepithelial permeability that does 
not involve the breakdown of tight junctions, the dissociation of the epithelial cells, or a decrease 
in claudin-1 expression in the tight junctions. The reasons for the difference between the current 
studies and the previous reports showing a breakdown of junctional complexes is unknown but the 
agonist concentration may play a role. Over-activation of TRPV4 by exogenous agonists does have 
pathological consequences. For example, i.v. administration of GSK1016790A caused circulatory 
collapse in mice, rats and dogs due to endothelial barrier function failure (33).  While the current 
studies did not explore the long term effects on the junctional complexes, it is important to consider 
the normal in vivo role of TRPV4.  It is unlikely that the endogenous regulation of the channel will 
lead to catastrophic breakdown of tight junctions. GSK1016970A has been shown to have 
nanomolar potency with EC50s between 1-5 nM in human, dog and bovine cellular assays and 
EC50s of 10-18.5 nM in rodents (33). The PCP-R cells are exquisitely sensitive to the agonist with 
~50% of cultures resulting in an irreversible change in conductance at both 5 and 10 nM. The 
maximum agonist concentration that does not result in an irreversible change in 
resistance/conductance appears to be 3 nM and we have chosen, therefore, not to use higher 
concentrations in the majority of the experiments.  
 
When examining the transepithelial ion fluxes using short-circuit current electrophysiology, the 
initial direction of the TRPV4-mediated ion flux is consistent with anion absorption and/or cation 
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secretion.  Given that the CP is, on a per gram basis, one of the most secretory epithelia in the 
body, it is likely that cation secretion accounts for the majority of the electrolyte flux within the 
first few minutes.  Thereafter the net transport indicated by the SCC plateaus briefly and then 
reverses indicating a complex mixture of net electrogenic fluxes.   
 
Although Na+ secretion cannot be discounted, amiloride, an inhibitor of the epithelial Na+ channel 
found in many high-resistance epithelia, did not block the TRPV4-mediated flux (data not shown).  
The role of other Na+ transporters was not examined in these studies.  TRPV4 is a cation channel 
that, when activated, transports Ca2+ into cells. The most likely candidate for the cation secretion 
was postulated to be K+ channels, specifically Ca2+-activated K+ channels.  The importance of 
Ca2+-activated K+ channels in CP epithelia has been recognized for over three decades (17) but the 
identification has remained elusive. RT-PCR of the PCP-R cells indicated the presence of SK2 and 
IK but not SK1 SK3, or BK.  In agreement with these data an inhibitor of BK (iberiotoxin) did not 
block the TRPV4-stimulated changes in transepithelial ion flux or conductance in the PCP-R cell 
line.  While the SK channels are differentially sensitive to apamin, 100 nM of this bee venom 
should have blocked the all three channels (32).  However, pretreatment with apamin did not block 
the TRPV4-mediated ion flux or conductance change.  Likewise, preincubation with tamapin, Lei-
Dab7 or scyllatoxin, relatively specific inhibitors of SK2 (1, 32) did not inhibit GSK1016790A-
stimulated electrogenic ion flux or conductance (data not shown).  Thus, although SK2 appears to 
be present in the cell line, it is not involved in TRPV4 agonist-stimulated ion flux or conductance 
changes. 
 
IK, also known as KCNN4, has recently been shown to have 3 isoforms in the rat.  KCNN4a-
specific transcripts were found in smooth muscle while KCNN4b and KCNN4c were expressed in 
epithelial cells (3).  Interestingly, these latter two isoforms show a divergence in TRAM34 
sensitivity as well as epithelial cell polarity.  In intestinal cells, the IC50 for the inhibitory effect of 
TRAM34 on the KCNN4b isoform was in the sub-micromolar range while the IC50 for the 
KCNN4c isoform was approximately an order of magnitude higher in the low micromolar range 
(3, 4, 15).  The KCNN4b isoform was localized to the basolateral membrane of intestinal cells 
where it was involved in K+ absorption while the KCNN4c isoform was localized to the apical 
membrane where it is involved in K+ secretion (4, 15, 28).   
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Low dose (1 M) TRAM34 did not affect TRPV4-stimulated ion flux or conductance while 50 
M completely inhibited both parameters.  These data are consistent with the involvement of the 
Kcnn4c isoform of the IK channel.  A moderately high dose of TRAM34 (25 M) completely 
inhibited TRPV4-mediated ion flux and conductance changes when added to the apical bathing 
media indicating an apical localization of this isoform as found in previous studies (4, 15, 28).  
However, addition of the same concentration of the inhibitor to the serosal bathing media partially 
inhibited TRPV4-mediated ion flux and substantially, but not completely, blocked the increase in 
conductance.  These data indicate a relatively complex inhibitor effect that could be due to 
transepithelial permeability of the TRAM34 or to off-target effects of the inhibitor. In immune 
cells, micromolar concentration of TRAM-34 reduced lysophosphatidylcholine induced increases 
in intracellular calcium by inhibiting non-selective cation channels (24). Similar effects on non-
selective cation channels, including TRPV4, cannot be ruled out in the current experiments. Figure 
3.12 contains a diagram of the choroid plexus and the hypothesized placement of the IK channel 
based on the current studies.  Additional experiments will be necessary to clarify additional 
components that are likely to be contributing to the electrophysiological responses. 
 
In the 1980’s, a series of elegant electrophysiological experiments by Wright and colleagues in 
Necturus CP showed that the apical membrane accounted for more than 90% of the K+ 
conductance of the epithelial cells and suggested the presence of an apical Ca2+-activated K+ 
channel (17, 37) .  Our current studies are in agreement with this early work and suggest that the 
apical Ca2+-activated K+ channel is the KCNN4c isoform of IK. 
 
In summary, we have shown that activation of TRPV4 stimulates a striking change in 
transepithelial permeability accompanied by a transepithelial ion flux.  The effect of the TRPV4 
agonist appears to be specific because the effect is blocked by two chemically distinct antagonists.  
The lack of permeability change after antagonist pre-incubation further indicates that the agonist 
is not having a nonspecific effect on the epithelial cell junctions. Agents that block the increase in 
conductance also block the electrogenic transepithelial ion flux.  We hypothesize that the 
transepithelial ion flux is due to cation secretion because a preliminary study has indicated that 
TRPV4 antagonists are effective in decreasing the hydrocephalus in a model of the communicating 
form of the disease (8), thus suggesting that electrolyte flux into the CP is an integral component 
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of the response. A substantial portion of the transepithelial ion flux due to stimulation of a Ca2+-
activated K+ channel, IK.  The decreased sensitivity and the apical localization of the TRAM34 
effect in the CP cells indicates that the form of IK found in the CP is KCNN4c.  However, the 
sustained conductance change suggests that the response to TRPV4 stimulation is complex, likely 
involving electrogenic and electroneutral transporters.  Further experimentation will be necessary 
to determine the exact nature of the osmolyte permeability and which transport effects are primary 
and which are secondary. 
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Table 3.1 Primer pairs used for the RT-PCR with corresponding product sizes (bp). 
To confirm the presence or absence of the gene of interest for the K+ channels, two different 
primer pairs were used. Gapdh was used as a positive control in all RT-PCR experiments. 
 
Sus Scrofa 
gene 
Protein Primer Sequences 5' - 3' Product 
Size (bp) Forward Primer Reverse Primer 
Kcnn1 SK1 GGAAGAGGAAGAAGATGAGGAA GAGAGGAAAGTGATGGAGATGA 801 
  SK1 CTTCAGCATCTCCTCCTGGATC TGGATGGCTTGGAGGAACTTAC 432 
Kcnn2 SK2 AGAACCAGAATATCGGCTACAA TAAAAGCATGACTCTGGCAATC 488 
  SK2 TCTGATTGCCAGAGTCATGCTT CACGTGCTTTTCTGCTTTGGTA 418 
Kcnn3 SK3 AACACACAAAGCTGCTAAAGAA TCTGGAGTGGGGAGTTTTATTT 466 
  SK3 GGCGAGTACAAGTTCTTCTGGA TAGCTTGCAGGAACTTCCTCTG 685 
Kcnn4 IK CTGGTTTGTGGCCAAGTTGTAC TCCTACGCGTGTGTTTGTAGAA 419 
  IK ATCAGCATTTCCACGTTCTTGC TCCTACGCGTGTGTTTGTAGAA 799 
Kcnma1 BK ACTTGGAAGGAGTCTCAAATGA ATCTGATCATTGCCAGGGATTA 445 
  BK TTACTGCAAGGCCTGTCATGAT AAGGTCCGTATCAGGGTAAGGA 990 
Trpv4 TRPV4 AGATTGGGATCTTTCAGCACAT AGCAAGTAGACCAGCAGGAAAC 724 
Gapdh GAPDH TTTTAACTCTGGCAAAGTGGAC CATTGTCGTACCAGGAAATGAG 884 
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Figure 3.1 Development of transepithelial resistance of the PCP-R cell line.  
Development of transepithelial resistance of the PCP-R cell line after seeding on Transwell 
supports. The bars are a composite of control values from multiple electrophysiological 
experiments conducted over a two-year period.  In each case the resistance was measured just 
before the addition of an electrolyte transport effector, i.e., after the cells were mounted in the 
Ussing chambers and allowed to reach a stable baseline current.  The bars represent the mean 
+S.E.M. for the number of experiments listed. 
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Figure 3.2: Effect of TRPV4 agonist and antagonists on transepithelial conductance and 
electrogenic ion flux in the PCP-R cell line.   RN1734 or HC067047, specific TRPV4 
antagonists were added to the PCP-R cultures indicated by the open circles and grey squares at 
time T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to all cultures.  
The symbols represent the means + S.E.M. for the number of experiments indicated on the 
graphs. SCC = short-circuit current. * indicates statistically significant differences between the 
two conditions (p < 0.02) as measured by Students t-test, paired data. 
 
94 
 
Figure 3.2 Effect of TRPV4 agonist and antagonists in the PCP-R cells. 
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Figure 3.3: Dose response for the TRPV4 agonist GSK1016790A effect on transepithelial 
conductance and ion movement in the PCP-R cell line. Concentrations of 0.1, 1, 3, 5, and 10 
nM GSK1016790A were added to the PCP-R cultures at T = 0 minutes. Cell cultures whose 
resistance drops below 100 Ω*cm2 or the conductance rises higher than 10 mS/cm2 were 
considered irreversibly altered by the agonist and were not included. The same experimental 
data were used for both graphs. Delta () SCC is defined as the difference in SCC between the 
value just before agonist addition and the value at the point of the maximal response  The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs. 
SCC = short-circuit current. 
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Figure 3.3 Dose response for TRPV4 agonist GSK1016790A in PCP-R cells. 
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Figure 3.4: Dose response for the TRPV4 antagonist RN1734 pre-treatment in the PCP-R cell 
line. Concentrations of 5, 25, and 50 µM RN1734 were added to the PCP-R cultures at T = -
10 minutes. At time 0, the TRPV4 agonist GSK1016790A was added to all cultures. The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs. 
SCC = short-circuit current. 
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Figure 3.4 Dose response for TRPV4 antagonist RN1734 pre-treatment in PCP-R cells. 
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Figure 3.5: Reversibility of a TRPV4 agonist response by a TRPV4 antagonist.  At time 0 the 
TRPV4 agonist GSK1016790A was added to all culture.  RN 1734, a TRPV4 antagonist, was 
added to the cultures indicated by the open circles 15 minutes after the addition of the agonist. 
The symbols represent the means + S.E.M. for the number of experiments indicated on the 
graphs. SCC = short-circuit current.  * indicates statistically significant differences between 
the two conditions as measured by a 2-tailed Student’s t-test (p < 0.02). 
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Figure 3.5 Reversibility of a TRPV4 agonist response by a TRPV4 antagonist.  
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Figure 3.6 Immunohistological staining of claudin 1 in the PCP-R cell line. 
Cells were stained with DAPI (blue) to visualize nuclei and anti-claudin-1 antibody (green) to 
show the presence of tight junctions. Treated cells were pre-incubated with TRPV4 agonist, 
GSK1016790A (3nM), for 10 minutes before fixation and staining. Negative control cells were 
stained with DAPI and secondary antibody only. This figure is representative of 4 independently 
conducted experiments. Scale bars represent 25µm. 
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Figure 3.7: RT-PCR of selected ion channels in the PCP-R cell line. Left hand gel shows the 
results of RT-PCR of Ca2+-activated K+ channels.  The gel shows expression of only SK2 and 
IK among the calcium activated potassium channels.  SK1, SK3 and BK were all notably 
absent. The second gel shows expression of TRPV4  For any channels not present, additional 
primer sets were utilized to confirm absence of the cDNA.  
SK = small conductance K+ channel; IK = intermediate conductance K+ channel; BK = big 
conductance K+ channel; TRPV4 = transient receptor potential vanilloid 4; GAPDH = 
glyceraldehyde 3-phosphate dehydrogenase  
 
103 
 
 
 
Figure 3.7 RT-PCR of selected ion channels in the PCP-R cell line. 
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Figure 3.8: Effect of pre-treatment with a BK channel inhibitor on TRPV4 agonist stimulated 
increases in transepithelial conductance and ion transport.  Iberiotoxin, an inhibitor of big 
conductance potassium (BK) channel was added to the PCP-R cultures indicated by the open 
circles at time T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to 
all cultures.  The symbols represent the means + S.E.M. for the number of experiments 
indicated on the graphs. SCC = short-circuit current. 
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Figure 3.8 Effect of BK channel inhibitor on TRPV4-mediated responses. 
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Figure 3.9: Effect of pre-treatment with an inhibitor of SK channels on TRPV4 agonist 
stimulated increases in transepithelial conductance and ion transport. Apamin, an inhibitor of 
small conductance potassium (SK) channels, was added to the PCP-R cultures indicated by the 
open circles at time T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added 
to all cultures.  The symbols represent the means + S.E.M. for the number of experiments 
indicated on the graphs.  SCC = short-circuit current. 
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Figure 3.9 Effect of SK channel inhibitor on TRPV4-mediated responses. 
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Figure 3.10: Effect of pre-treatment with high and low doses of an IK channel inhibitor on 
TRPV4 agonist stimulated increases in transepithelial conductance and ion transport. 
TRAM34, an inhibitor of intermediate conductance potassium (IK) channels, was added 
bilaterally to the PCP-R cultures indicated by the open circles or inverted triangles at time T = 
-10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to all cultures.  The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs.  
SCC = short-circuit current.  The positive control data (GSK1016790A only) shown in this 
figure are the same data that are shown in figure 11. * indicates statistically significant 
differences between the experimental and control (solid circles) groups (p < 0.02) as measured 
by Students t-test, paired data.  indicates statistically significant differences between the two 
experimental (open circles and inverted triangles) groups (p < 0.02) as measured by Students 
t-test, paired data. 
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Figure 3.10 Effect of high/low doses of IK channel inhibitor on TRPV4-mediated responses. 
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Figure 3.11: Sidedness of the effect of an inhibitor of IK channels on TRPV4 agonist stimulated 
increases in transepithelial conductance and ion transport. TRAM34, an inhibitor of 
intermediate conductance potassium (IK) channels, was added to either the serosal or apical 
bathing media of the PCP-R cultures indicated by the open circles or inverted triangles at time 
T = -10 minutes.  At time 0, the TRPV4 agonist GSK 1016790A was added to all cultures.  The 
symbols represent the means + S.E.M. for the number of experiments indicated on the graphs.  
SCC = short-circuit current.  The positive control data (GSK1016790A only) shown in this 
figure are the same data that are shown in figure 10. * indicates statistically significant 
differences between the experimental and control (solid circles) groups (p < 0.02) as measured 
by Students t-test, paired data.  indicates statistically significant differences between the two 
experimental (open circles and inverted triangles) groups (p < 0.02) as measured by Students 
t-test, paired data. 
 
111 
 
Figure 3.11 Sidedness of IK channel inhibitor on TRPV4-mediated responses.  
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Figure 3.12 Diagram of selected transporters in the choroid plexus epithelia. 
The left hand side of the diagram illustrates that the choroid plexus within the ventricle is 
continuous with the ependymal cells. Choroid plexus cells (dark purple) are increased in size 
compared to ependymal cells (light purple). On the right-hand part of the diagram, individual 
choroid plexus cells are shown as polarized with transporters on both the apical and basolateral 
membranes, and connected by tight junctional proteins.  
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 INFLAMMATORY EFFECTS ON TRPV4 IN THE 
CHOROID PLEXUS 
4.1 Preface 
The data in this chapter will be submitted in Spring 2019 to the American Journal of Physiology: 
Cell Physiology, I am first author for the following journal article. In the drafting of the article, I 
was responsible for writing the manuscript, designing and conducting all experiments, analyzing 
all data, and designing and formatting all figures. Exceptions to my contributions include the qPCR 
experiments performed by my co-author, Daniel Preston, maintenance of the animal colony and 
collection of rat CSF performed by our laboratory technician, and the collection of human CSF 
performed by my co-authors at Riley’s Hospital for Children in Indianapolis, IN. 
4.2 Inflammatory mediator effects on TRPV4 function in the choroid plexus 
Stefanie Simpson1, Daniel Preston1, Daniel Fulkerson2, Karl Balsara2, and Bonnie Blazer-Yost1 
 
1. Department of Biology, Indiana University-Purdue University at Indianapolis, Indiana 
2. Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis 
4.3 Introduction 
Hydrocephalus, also known as "water on the brain," is a condition characterized by an imbalance 
in cerebrospinal fluid (CSF) production and/or reabsorption (communicating) or by a blockage in 
the CSF circulation (non-communicating). This can result in the accumulation of CSF and 
enlargement of the ventricles in the brain, leading to an increase in hydrostatic pressure, neuronal 
destruction, behavioral and cognitive changes, gait changes, vision problems, and potentially death 
(52). The condition can occur at any age and can develop from a number of causes including head 
trauma, intracranial hemorrhage, infection, inflammation, brain tumor, genetic defect or 
neurodegenerative disease (23, 39-47). Currently, the only approved treatments in humans involve 
invasive brain surgery, underscoring the need to better understand the physiology of this 
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debilitating disease in order to find a pharmacological treatment. One of the key components of 
this is the regulation of fluid and electrolytes during the production of CSF. 
The main production of CSF comes from the choroid plexus (CP), present in the lateral, third, and 
fourth ventricles (6). Composed of a high resistance barrier epithelium that surrounds a network 
of capillaries, the CP epithelial cells regulate the transport of ions and water between the ventricles 
and capillaries via electrolyte transporters, thus controlling the production and movement of CSF. 
Aberrant regulation of these transporters could be a causative agent leading to the emergence of 
hydrocephalus.  
 
Previous data suggest a link between transepithelial ion movement in choroid plexus epithelial 
cells and the cation channel, Transient Receptor Potential Vanilloid-4 (TRPV4) (5, 47, 50). TRPV4 
is a mechano-, osmo-, and temperature-sensitive, non-selective, calcium-permeable cation channel 
that can serve as a hub protein for the activation of other transporters (2-4). For example, TRPV4 
activation can lead to an influx of calcium into the cells, which subsequently stimulates calcium 
activated ion channels, such as the intermediate conductance potassium channels (5). Once these 
channels are activated, there is the potential for significant ion flux across the epithelia, resulting 
in compensatory water movement and a change in CSF production. TRPV4 also acts as a hub 
protein in that it can be modulated through a number of stimuli, including pressure or flow 
alterations, osmotic changes, temperature fluctuations, and chemical activators, such as cytokines 
and inflammatory mediators (2-5). In particular, the latter activators can also be seen in 
neurodegenerative states related to hydrocephalus. Indeed, it has been established that the 
inflammatory lipid endocannabinoid anandamide (AEA) and its metabolites, including 
arachidonic acid (AA), are capable of activating the channel (4). In addition, cytochrome P450 
epoxygenases, cyclooxygenases, and lipoxygenases can metabolize AA into anti-inflammatory 
factors epoxyeicosatrienoic acids (EETs), prostaglandins, and hydroperoxides respectively, which 
are also believed to stimulate TRPV4 activity (4, 7). 
 
Microglia, the macrophage-like cells of the central nervous system (CNS), can be triggered to 
release pro-inflammatory cytokines in response to abnormal protein accumulation or neuronal 
injury from chemical or physical means (8, 9). It is possible that such inflammation is associated 
with the development of hydrocephalus in various neurological disorders (39, 41, 48-49, 51). Pro-
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inflammatory cytokines found upregulated in neurodegenerative states include interleukin (IL)-1β 
and tumor necrosis factor (TNF)-α. IL-10 is a well-documented anti-inflammatory cytokine also 
found in various hydrocephalic-associated diseases. IL-4 is also an anti-inflammatory compound 
while other cytokines have more complex actions. TGF-β and IL-6 have both been implicated in 
pro- as well as anti-inflammatory effects (9-15). These cytokines can, therefore, potentially play a 
role in the development and pathology of hydrocephalus. 
 
As an in vitro model, the high resistance porcine choroid plexus-Rheims cell line (PCP-R) can be 
utilized to monitor changes in transepithelial ion flux and barrier permeability in response to 
factors that modulate electrolyte transporters (5). The polarity and barrier function exhibited by 
this cell line allows for experimentation modeling changes in the barrier function of choroid plexus 
in vivo (16). Using a TRPV4 agonist, GSK1016790A, we are able to stimulate TRPV4 activation 
and observe changes in ion flux and transepithelial conductance in the presence of various 
cytokines and inflammatory mediators.  
 
The Wpk rat is an orthologous model of the ciliopathy Meckel-Gruber Syndrome (17, 27). This in 
vivo model contains a genetic single point mutation on chromosome 5 on the TMEM67 gene, 
resulting in the homozygous recessive animals that develop both severe polycystic kidney disease 
(PKD) and a rapidly-progressing form of hydrocephalus (17, 27). In their adulthood, heterozygous 
animals develop an asymmetrical mild form of hydrocephalus, while showing no signs of PKD. 
Because they do not develop PKD, these animals are therefore devoid of the potentially 
confounding variable of renal insufficiency (1). With these in vivo and in vitro models, we are able 
to observe potential signs of inflammation in the brain and examine its effects on the development 
of hydrocephalus and TRPV4 function. 
 
While inflammation caused by hydrocephalus in the animal model is not evident, this article will 
show how pro-inflammatory cytokines and inflammatory mediators can play a role in the 
development of the disease. Specific cytokines alter the function of TRPV4 in the choroid plexus 
epithelia, providing more insight into the role of the cation channel in neurodegenerative states 
and suggesting this hub protein as a potential therapeutic target. 
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4.4 Materials and Methods 
Cell Culture: PCP-R cells were grown on 0.4 µm pore diameter Transwell filters (Corning) until 
the cultures developed a high transepithelial electrical resistance (TER) (10-12 days). Only 
cultures with resistances above 500 Ωcm2 were utilized. During experimental protocols that result 
in a change in resistance, cells that drop below 100 Ωcm2 were also removed from analysis as their 
junctional complexes appear irreversibly altered. Cells were fed three times weekly with feeding 
media containing DMEM with 4.5 g/L glucose, 3.7 g/L NaHCO3, 5.71 g/L HEPES, 10% fetal 
bovine serum (Atlanta), 100 U/mL penicillin, 100 mg/mL streptomycin, and 5 µg/ml insulin. Each 
plate contained 6 filters in 6 different wells. Transwells were bathed in 2 mL feeding media on the 
basolateral (bottom) side of the membrane and 1.5 mL feeding media on the apical (top) side of 
the membrane.  
 
Real Time (RT)-PCR: For the RT-PCR, cells were grown in 75 cm2 flasks until confluent. The 
monolayers were trypsinized, collected, and RNA from the cells extracted following the 
manufacturer’s instructions for the New England BioLabs Monarch Total RNA Miniprep Kit 
(#T2010S). No template controls and cDNA were prepared by following manufacturer’s protocol 
for the New England BioLabs LunaScript RT SuperMix Kit (#E3010S). Three primer sets for each 
gene were generated using Primer3 with mRNA sequences of the gene in question and tested on a 
temperature gradient. Only those primers used in the final images were included in Table 4.1. Sus 
scrofa mRNA sequences were obtained from Ensembl and additionally confirmed with sequences 
from the NCBI database. Forward and reverse primers (IDT) were combined with cDNA 
(approximately 500 ng) and GoTaq Green Master Mix (Promega) to perform gradients of PCR to 
determine the optimal annealing temperature. PCR products were then run on 1.5% agarose gels 
with ethidium bromide and 1kb flanking ladders. Gels were imaged using a ChemiDoc XRS 
imager (Bio-Rad, Hercules, CA). 
 
Electrophysiology: Electrophysiological techniques were conducted by excising and mounting 
confluent (10-12 days) Transwell filters in Ussing chambers which are attached to a DVC-1000 
Voltage/Current Clamp (World Precision Instruments) using voltage and current electrodes. To 
each side of the chamber, 10 mL of serum-free media was added. The chambers were water 
jacketed to allow the cells and media to be kept at a consistent physiological temperature (37˚C). 
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Furthermore, the media was continuously oxygenated and circulated by bubbling 5% CO2/O2 
directly into the media. Following clamping of the spontaneous transepithelial potential difference 
to zero for an equilibration period of at least 30 minutes, experimental compounds were added to 
the apical and/or basolateral membranes by means of the serum-free media and the cultures were 
monitored for changes in short circuit current (SCC) and TER. Transepithelial resistance is a 
measure of changes in epithelial barrier function and was measured every 200 seconds through a 
2mV pulse. The instantaneous change in SCC from the pulse was used to calculate TERs by means 
of Ohm’s Law. These resistance calculations were converted to conductance by taking the inverse 
of the resistances. These parameters provided real time information about transepithelial ion flux 
in response to modulators of ion channels or intracellular signaling molecules. In each experiment, 
the cells were pre-incubated on both basolateral and apical sides with the experimental compounds 
for either 10 or 20 minutes or 24 hours prior to addition of TRPV4 agonist GSK1016790A. 
 
Statistics: Statistics were performed using Two-tailed Students t-test in Sigma Plot 13. p < 0.05 is 
considered significant. 
4.5 Results 
In order to determine the ability of the PCP-R cell line to respond to and/or produce various 
cytokines and inflammatory mediators, RT-PCR was performed to identify specific genes of 
interest. Toll-like receptors (TLRs) are the major membrane-bound proteins necessary for cytokine 
reception and production (25, 26). Within the pig genome, ten different TLRs have been described 
(TLR1-TLR10) (24). mRNA for all of these receptors were found to be present in the PCP-R cell 
line (Figure 4.1A).  
 
Arachidonic acid (AA) is a substrate for the production of various inflammatory mediators, some 
of which can stimulate TRPV4 (4, 30, 31). Therefore, we investigated which of the enzymes 
necessary to metabolize AA were present in the cells. Reference Figure 4.1C for a simplified 
summary of AA metabolism. Cytochrome P450 epoxygenases (CYP) are responsible for the 
production of EETs from AA. EETs have been reported to be a main activator of TRPV4 (30). 
While there are many known isoforms of Cyp genes, only two of these have currently been 
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sequenced in the pig: Cyp2c42 and Cyp2e1. Neither of these isoforms were present in the porcine 
CP cells. Another pathway of AA metabolism utilizes lipoxygenases to produce hydroperoxides. 
In pigs, there are currently four lipoxygenase (Alox) gene sequences available: Alox5, Alox12b, 
Alox15, and Alox15b. Of these, only Alox15 and Alox15b were present in the PCP-R cells. Finally, 
prostaglandins are formed when AA is metabolized by cyclooxygenases (COX) 1 or 2. Both Cox1 
and Cox2 mRNA were found in the cell line (Figure 4.1B).  
 
Utilizing electrophysiology to measure changes in transepithelial ion flux and epithelial barrier 
permeability, several pro- and anti-inflammatory cytokines and mediators that were hypothesized 
to be important in hydrocephalic development were tested to assess how they would affect the 
basal characteristics of the PCP-R cells and subsequently their response to the TRPV4 agonist 
GSK1016790A. Interleukin (IL)-1β and Tumor Necrosis Factor (TNF)-α are two of the most 
prominent pro-inflammatory cytokines seen in neurodegenerative diseases (9-15). Upon pre-
incubation of the PCP-R cells with either cytokine for 24 hours, both cytokines had significant 
effects on TRPV4-mediated ion flux, measured as short-circuit current (SCC), albeit on different 
phases of the ion transport response. IL-1β caused an attenuation of the agonist response 
particularly in the early (0-15 minute) timeframe while TNF-α caused an expediated increase in 
SCC toward baseline in late response to the agonist. Interestingly, these two pro-inflammatory 
cytokines had opposite effects on transepithelial permeability, measured as conductance. TNF-α 
caused no change in conductance after a 24-hour incubation compared to the control. 24-hour 
incubations with IL-1β caused a significant attenuation in the TRPV4 agonist-mediated change in 
conductance which paralleled the effect on transepithelial ion flux measured as SCC (Figures 4.2 
& 4.3). 
 
Interestingly, pre-incubation with TGF-β, which has been reported to have both pro- and anti-
inflammatory effects, had similar significant attenuation effects as IL-1β at 24 hours. However, 
the same treatment with IL-6, another pro- and anti-inflammatory cytokine, yielded no significant 
response (Figures 4.6 & 4.7). Finally, the cells were pre-incubated with the cytokines IL-10 and 
IL-4. Neither of these anti-inflammatory cytokines had any long-term effect on either 
transepithelial ion flux or conductance (Figures 4.4 & 4.5).  
 
123 
 
NF- κB is a transcription factor often associated with pro-inflammatory signaling pathways. Pro-
inflammatory cytokines, mainly IL-1 and TNF-α, are considered activators of NF- κB, which can 
have downstream effects on the activation of inflammation and further production of cytokines 
(18). As such, the PCP-R cells were pre-incubated with a selective inhibitor for NF-κB, PDTC 
(19). By inhibiting NF-κB 10 minutes prior to adding the TRPV4 agonist, there was a potentiation 
of the intermediate (5-10 min) phase of TRPV4-mediated ion flux. There was also an initial 
increase in permeability compared to the control that is entirely consistent with the time-course of 
the SCC response. However, this change did not persist; permeability returned to control levels 30 
minutes after agonist addition (Figure 4.8). As NF-κB is a transcription factor, it might take longer 
for its true effects to become evident. Therefore, we also inhibited the pro-inflammatory mediator 
24 hours prior to adding the TRPV4 agonist (Figure 4.9). In this instance a very different result 
occurred. Transepithelial ion flux was significantly reduced compared to the control. Furthermore, 
the initial conductances in these pre-treated cells were higher than the controls prior to agonist 
addition. However, the cellular permeability did not increase substantially after agonist addition 
as seen in the control. 
 
AA and its metabolite, 5,6-EET, are often cited as being activators of TRPV4 (4, 9, 30, 31). 
However, when the PCP-R cells were pre-incubated with AA for 10 minutes, the transepithelial 
ion movements caused by the TRPV4 agonist within the initial and intermediate timeframes were 
substantially inhibited, while the barrier permeability was not altered (Figure 4.10). When 
incubated with the anti-inflammatory AA metabolite, 5,6-EET, a different reaction occurred. In 
regard to ion flux (SCC), the late phase was inhibited, and this was mirrored in a trend toward a 
decrease in conductance although the latter did not reach statistical significance (Figure 4.11). 
 
In order to further elucidate the role of the AA pathway in the function of TRPV4, we utilized 
various inhibitors for the enzymes involved in AA metabolism to determine which of the pathways 
were involved in TRPV4 activity. Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) 
able to prevent the metabolism of AA into the pro-inflammatory prostaglandins by non-selectively 
inhibiting both cyclooxygenases (4, 7, 20-22). However, indomethacin caused no differences in 
TRPV4-mediated ion movement or permeability compared to the control (data not shown). 
Eicosatetraynoic acid (ETYA) is a suicide inhibitor of all cyclooxygenases and lipoxygenases, 
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which produce prostaglandins and leukotrienes, respectively. When added to the cells 20 minutes 
prior to the TRPV4 agonist, there were significant attenuations of both the SCC and conductance 
changes. Finally, we pre-incubated the cells with SKF-525A, a non-specific inhibitor of 
cytochrome P450, responsible for the production of EETs. This inhibitor caused a complete 
inhibition of both transepithelial ion flux and changes in cellular permeability caused by TRPV4 
activity (Figure 4.10). 
4.6 Discussion 
TLRs are often found on microglia, astrocytes, and other immune cells and are well known for 
playing a key role in the initiation of the innate immune response to pathogen-associated molecular 
patterns (PAMPs). But the TLRs not only play a major role in a cell’s ability to respond to 
inflammatory reactions, but they also enable the cells to contribute to the inflammation. When a 
cytokine ligand binds to the TLRs, this can cause a cascade of events leading to activation of 
transcription factors NF-κB and AP-1 and subsequent cytokine production (24, 25). In particular, 
TLR4 is best known for producing key pro- and anti-inflammatory cytokines, such as TNF-α, IL-
6, and IL-10, and is most often associated with inflammation (24, 25). It is also of interest that 
TLRs have been found to alter with age (25). Specifically, pro-inflammatory cytokine production 
increases while secretion of anti-inflammatory cytokines decreases. It is with this in mind that 
TLRs have been associated with age-related inflammatory neurodegenerative diseases, such as 
ischemic stroke, Alzheimer’s disease, and multiple sclerosis (25). Therefore, the finding that the 
PCP-R cell line contains all 10 of the known porcine TLRs signifies that CP cells have the potential 
to not only respond to various inflammatory signals but can also lead to the secretion of several 
different cytokines into the CSF. This could also suggest that with age, the TLRs of the CP cells 
could cause increases in cytokine production and contribute to neurodegenerative states, including 
hydrocephalus. 
 
In studies using lung and endothelial tissue, TRPV4 antagonists have been found to reduce 
pulmonary edema and protect against sepsis, respectively. In both studies, TRPV4 inhibition was 
also found to decrease inflammation and cytokine production (28, 29). This would suggest that 
TRPV4 acts in a pro-inflammatory manner. To confirm this in the brain, we looked at various 
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types of cytokines, including pro-inflammatory, anti-inflammatory, and paradoxical pro- and anti-
inflammatory cytokines. Of these, the anti-inflammatory cytokines showed no detectable effect on 
TRPV4-mediated ion flux, and the pro-inflammatory cytokines had the most significant effects on 
TRPV4 activity after incubating with the cells for 24 hours. Interestingly, the responses seen with 
the two prominent pro-inflammatory cytokines were not the same. While IL-1β showed a 
weakening of the entire response with both SCC and conductance changes reduced, TNF-α only 
caused a heightened return to electroneutral SCC but did not substantially alter conductance 
compared to the control. In addition to this, the paradoxical pro- and anti-inflammatory cytokines, 
TGF-β1 and IL-6, had varying effects with TGF-β1 causing strikingly similar results as IL-1β but 
no significant changes with IL-6. It is possible that these cytokines alter whether they act via pro- 
or anti-inflammatory pathways depending on physiological cues. While it cannot be assumed that 
all pro-inflammatory pathways cause an attenuation or inhibition of the response, it is most likely, 
based upon our observations, that TGF-β1 is acting in a pro-inflammatory manner while IL-6 is 
more anti-inflammatory in the CP cells. Together, these data imply that pro-inflammatory 
cytokines diminish TRPV4 function. From this, there are some possibilities of how TRPV4 is 
functioning in the response. It could be that TRPV4 acts to produce pro-inflammatory cytokines 
and is diminished in a negative feedback loop when cytokines are in excess. This theory would not 
disagree with the previous studies in lung and endothelial tissue as pro-inflammatory cytokine 
production decreased with TRPV4 inhibition (28, 29). The finding that inhibition of the pro-
inflammatory transcription factor NF-κB initially caused a potentiation of TRPV4-mediated ion 
flux and permeability changes cannot be easily explained. It is possible that this increase is due to 
the sudden increase in barrier permeability as ions are more easily able to move across the 
membrane. After 24 hours of inhibition, the permeability remains high, but stimulation of TRPV4 
does not cause additional increase in conductance and results in significantly attenuated ion flux 
responses. Therefore, NF-κB activation and possibly its downstream inflammatory effectors can 
be considered contributors to TRPV4-mediated ion flux and permeability changes. This also 
further suggests that TRPV4 is involved in the production of cytokines and regulation of 
inflammation. 
 
Several publications have reported that AA and its metabolites are able to cause substantial 
elevation of [Ca2+]i by activating TRPV4. Specifically, these studies cite EETs as the predominant 
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activator of the cation channel (4, 9, 30, 31). Therefore, we hypothesized that TRPV4 activity 
would be potentiated after pre-incubation with either of these compounds and were surprised to 
find this not to be the case. From our data, we can see that AA added in excess causes an inhibition 
of TRPV4’s response. It is then possible that AA metabolism is required for TRPV4 activity, but 
that excess AA (i.e. inflammation) causes a down regulation of TRPV4. Under normal 
circumstances, endogenous AA is metabolized quickly so it likely does not have enough time to 
down regulate TRPV4 and the response is not seen. But when added in excess, we can see its 
inhibitory effect.  Taken together with our cytokine data, in which the pro-inflammatory cytokines 
also down regulate TRPV4, this would imply that inflammation acts to decrease TRPV4 activity. 
 
There is also controversy concerning which isoform of EET is responsible for activating TRPV4 
(32). It is possible that several different isoforms of EET act differently on TRPV4 between the 
many tissue and cell types where the channel lies. Currently, there are no known publications on 
the specific EET isoform responsible for TRPV4 activation in CP cells. While 5,6-EET is most 
often considered to be the activating isoform in other cell types, we found this not to be the case 
in CP cells. Furthermore, it is unknown whether the PCP-R cell line is able to produce EETs. The 
production of EETs occurs when AA is metabolized by the enzymes cytochrome P450 
epoxygenase, of which there multiple varieties (33). Currently, only two gene isoforms of these 
enzymes have been sequenced in pigs, Cyp2c42 and Cyp2e1, neither of which were present in the 
cells. However, there are several other isoforms still untested, including those most associated with 
EET production, CYP2C8, CYP2C9, CYP2C19 and CYP2J2 (33). Therefore, these data cannot 
lead to the conclusion that there are no cytochrome P450 epoxygenases present. Furthermore, the 
SKF-525A CYP450 inhibitor had dramatic inhibitory effects on TRPV4-mediated ion flux and 
permeability changes. This implies that EET is indeed the leading cause of TRPV4's effect. It is 
possible that there is a threshold to EETs’ effect on TRPV4. Thus, even though it is added in excess 
to the cells, it would be unable to further activate TRPV4 more so than the agonist is capable. More 
than likely, though, a different EET isoform other than 5,6-EET is affecting TRPV4 in the CP. 
 
We determined the presence and effects of the various other AA metabolites in the CP cells. Both 
isoforms of cyclooxygenase were present in the PCP-R cells, meaning that the cells are able to 
produce prostaglandins, prostacyclin, and thromboxane A2 (34). However, inhibition of both 
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COX1 and COX2 with the NSAID Indomethacin did not alter the effects of TRPV4 activation in 
the cells. Thus, these metabolites likely do not play a role in TRPV4-mediated pathways. 
 
We also looked closer at the lipoxygenase (LOX) pathway of which there are seven known gene 
isomers: Aloxe3, -5, -5ap, -12, -12b, -15, and -15b (35). Of these, Alox12b, -e3, and -15b are found 
in the skin and other epithelial cells and Alox5, -12, and -15 are located primarily in immune cells. 
Many of the isomers have been reported in different forms of cancers, but all of them can be 
involved in inflammation (35). However, only Alox15 and Alox15b were found in our cell line of 
the four currently sequenced in pig. The enzymes encoded by these two isoforms have higher 
similarities compared to the other isoforms, hence the similar nomenclature (35). However, 
interestingly, only Alox15 is considered one of the isoforms that can be partially controlled by 
cytokines. Anti-inflammatory cytokines, such as IL-4 and IL-13, have the potential to increase 
expression of this gene, which can then decrease production of pro-inflammatory cytokines, such 
as IL-12 (35). The isoform has also been associated with maintaining dermal integrity through 
anti-inflammatory suppression of inflammation in the skin (38). On the other hand, Alox15 is also 
capable of increasing pro-inflammatory matrix metalloproteinase (MMP) expression and 
contributing to arthritic disease progression (36, 37). Once again, this leads to the question of 
whether TRPV4 is acting in a pro- or anti-inflammatory process. Less is known about the Alox15b 
isoform, but it has been implicated in decreasing epithelial barrier permeability (35). Thus, 
increases in this isoform could contribute to increases in transepithelial ion flux in the CP tissue. 
 
To better understand how lipoxygenases affect the cell line when TRPV4 is activated, we utilized 
ETYA to inhibit both cyclooxygenases and lipoxygenases. We already know that inhibiting the 
cyclooxygenases alone does not affect the cells. However, when both are inhibited, there is a partial 
inhibition of the TRPV4-mediated response. We also now know that inhibiting the CYP450s and 
subsequent EET production results in complete inhibition of the TRPV4-mediated response. What 
this could translate to is that although ETYA is specific for CYP450 inhibition, it could have partial 
inhibitory effects. It could also be that the other AA metabolites (prostaglandins, leukotrienes, etc.) 
work together with EETs to act on TRPV4. Thus, inhibiting the other metabolites does attenuate 
the response, but because the cells are still able to produce EETs, ETYA cannot completely inhibit 
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the response. Future experiments will investigate how these metabolites are related in their 
response. 
 
In summary, TRPV4 is negatively affected by pro-inflammatory cytokines and mediators. We also 
found that when arachidonic acid is added to choroid plexus cells, TRPV4-mediated transepithelial 
ion flux is diminished. Finally, we confirmed that in the choroid plexus, inhibition of EET 
production causes a completely inhibition of TRPV4-mediated transepithelial ion flux and cellular 
permeability changes. Therefore, in the choroid plexus, TRPV4 can be affected by increases in 
inflammation due to hydrocephalus and other neurodegenerative diseases. 
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Table 4.1 Primer sequences used for RT-PCR with corresponding product sizes (bp).  
Three different primer sets were generated and tested for each gene. Primers included in this 
table were utilized for Figure 4.1A & Figure 4.1B. Gapdh was used as a positive control. 
 
Sus 
Scrofa 
gene 
Protein Primer Sequences 5' - 3' Product 
Size (bp) Forward Primer Reverse Primer 
Tlr1 TLR1 TGTCCCACAACAAGTTGGAGAA TTGTGGGAAACTGAACACCTCA 650 
Tlr2 TLR2 TCCCAAATCTGCGAATCCTGAA ATGCAACCTCCGGACTGTTAAT 512 
Tlr3 TLR3 CGATGACCTCCCGGCAAATATA GAGATTTTCCAGTTGGAGCTGC 382 
Tlr4 TLR4 TTCTCTCCTGCCTGAGATCTGA ACTCCAGGTAGGTATTCCTGCT 555 
Tlr5 TLR5 TCCTGTGGTCTCTCTGATGCTA GGGTTCATACACTTCCCCCAAT 284 
Tlr6 TLR6 AGACAATCTTGTGCCATCCCAT GGCCCTTGAGTGAGTTCCAATA 409 
Tlr7 TLR7 GACACTAAAGACCCAGCAGTGA CTGAAGGGGCTTCTCAAGGAAT 297 
Tlr8 TLR8 CTGAGGCAGAACAGGATTTCCT TTCATCACCCAGTCTGTGACAG 542 
Tlr9 TLR9 GCCTACGAACTCTCAACCTCAA GGAAGTTCTCACTCAGGTCCAG 696 
Tlr10 TLR10 TCAGGTGCTTGCCCAGAAATAT TCTTGCCAGGATCAGAGTTTCC 717 
Cyp2c42 CYP2C42 TCCTGTCTGCTTCTCCTTTCAC GGGAGCACAGTCCAGGATAAAA 489 
Cyp2e1 CYP2E1 TCGAGATTTCACTGACACCCTG GTTAAAGTGCTGCAAGATGGCA 592 
Alox5 5-LOX TGACAGTGGATGAAGAACTGGG TGTTTTTGCCGTGTTTCCAGTT 259 
Alox12b 12R-LOX ACACCATCCAGATCAACAGCAT CCAGAGGACCAATAGGACGATG 602 
Alox15 12/15-LOX CAGGAGGATGAACTCTTTGGCT TCGAATATACCTCCGTCCGAGA 578 
Alox15b 15-LOX2 GCGAAATGCTGAGTTCTCCATC CAGGGTGGAATAGTTCAGCTGT 283 
Cox1 COX1 TCACCCGCAATACTATGAGCTC TGTGTGATAGGGAGGAGGACAT 510 
Cox2 COX2 CCCTTTCCAACTAGGCTTCCAA TAGTCGTCCTGGGATAGCATCT 529 
Gapdh GAPDH TTTTAACTCTGGCAAAGTGGAC CATTGTCGTACCAGGAAATGAG 884 
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Figure 4.1: RT-PCR in PCP-R cells. A) mRNA is present for all Toll-like receptors (TLR) 1-
10 in the pig. B) Results for various enzymes capable of arachidonic acid (AA) metabolism. 
Cytochrome P(CYP)450 epoxygenases, Cyp2c42 and Cyp2e1, are both absent. mRNA for 
lipoxygenase (Alox)15 and Alox15b are present whereas Alox5 and Alox12 are absent. 
Cyclooxygenase (Cox) 1 and 2 are both present. Gapdh was utilized as positive controls for 
each gel. Band product sizes can be found in Table 1. Ladder = 1kb. C) Diagram of AA 
metabolism via the three different pathways, pathway inhibitors, and subsequent metabolites.  
 
131 
 
A) 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
C) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 RT-PCR in PCP-R cells.
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Figure 4.2: Pre-treatment of PCP-R cells with pro-inflammatory cytokine IL-1β at 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. IL-1β was added to the PCP-R media on both basolateral and apical sides of the 
membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to 
basolateral side of the membrane only at T = 0 minutes. 24-hour incubation is signified by 
white circles.  GSK1016790A control is signified by black circles. Error bars signify mean 
±S.E.M. for number of experiments indicated. SCC = short circuit current. * = p < 0.05 against 
control.  
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Figure 4.2 Pre-treatment of PCP-R cells with IL-1β 24-hrs pre-TRPV4 agonist addition. 
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Figure 4.3: Pre-treatment of PCP-R cells with pro-inflammatory cytokine TNF-α at 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. TNF-α was added to the PCP-R media on both basolateral and apical sides of the 
membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to 
basolateral side of the membrane only at T = 0 minutes. 24-hour incubation is signified by 
white circles.  GSK1016790A control is signified by black circles. Error bars signify mean 
±S.E.M. for number of experiments indicated. SCC = short circuit current. * = p < 0.05 against 
control.  
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Figure 4.3 Pre-treatment of PCP-R cells with TNF-α 24-hrs pre-TRPV4 agonist addition. 
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Figure 4.4: Pre-treatment of PCP-R cells with anti-inflammatory cytokine IL-10 at 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. IL-10 was added to the PCP-R media on both basolateral and apical sides of the 
membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to 
basolateral side of the membrane only at T = 0 minutes. 24-hour incubation is signified by 
white circles.  GSK1016790A control is signified by black circles. Error bars signify mean 
±S.E.M. for number of experiments indicated. SCC = short circuit current. 
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Figure 4.4 Pre-treatment of PCP-R cells with IL-10 24 hrs pre-TRPV4 agonist addition. 
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Figure 4.5: Pre-treatment of PCP-R cells with anti-inflammatory cytokine IL-4 at 24-hours 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. IL-4 was added to the PCP-R media on both basolateral and apical sides of the 
membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to 
basolateral side of the membrane only at T = 0 minutes. 24-hour incubation is signified by 
white circles.  GSK1016790A control is signified by black circles. Error bars signify mean 
±S.E.M. for number of experiments indicated. SCC = short circuit current. 
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Figure 4.5 Pre-treatment of PCP-R cells with IL-4 24 hrs pre-TRPV4 agonist addition 
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Figure 4.6: Pre-treatment of PCP-R cells with pro- and anti-inflammatory cytokine TGF-β1 at 
24-hours prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance 
was measured. TGF-β1 was added to the PCP-R media on both basolateral and apical sides of 
the membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to 
basolateral side of the membrane only at T = 0 minutes. 24-hour incubation is signified by 
white circles.  GSK1016790A control is signified by black circles. Error bars signify mean 
±S.E.M. for number of experiments indicated. SCC = short circuit current. * = p < 0.05 against 
control.  
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Figure 4.6 Pre-treatment of PCP-R cells with TGF-β1 24 hrs pre-TRPV4 agonist addition 
142 
 
  
Figure 4.7: Pre-treatment of PCP-R cells with pro- and anti-inflammatory cytokine IL-6 at 24-
hours prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was 
measured. IL-6 was added to the PCP-R media on both basolateral and apical sides of the 
membrane at T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to 
basolateral side of the membrane only at T = 0 minutes. 24-hour incubation is signified by 
white circles.  GSK1016790A control is signified by black circles. Error bars signify mean 
±S.E.M. for number of experiments indicated. SCC = short circuit current.  
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Figure 4.7 Pre-treatment of PCP-R cells with IL-6 24 hrs pre-TRPV4 agonist addition 
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Figure 4.8: Pre-treatment of PCP-R cells with NF-κB inhibitor PDTC at 10 minutes prior to 
TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was measured. 
PDTC was added to the PCP-R media on both basolateral and apical sides of the membrane at 
T = -10 minutes. TRPV4 agonist GSK1016790A was added to basolateral side of the 
membrane only at T = 0 minutes. 10-minute incubation is signified by white circles.  
GSK1016790A control is signified by black circles. Error bars signify mean ±S.E.M. for 
number of experiments indicated. SCC = short circuit current. * = p < 0.05 against control. 
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Figure 4.8 Pre-treatment of PCP-R cells with PDTC 10 min pre-TRPV4 agonist addition. 
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Figure 4.9: Pre-treatment of PCP-R cells with NF-κB inhibitor PDTC at 24-hours prior to 
TRPV4 agonist addition. Effect on transepithelial ion flux and conductance was measured. 
PDTC was added to the PCP-R media on both basolateral and apical sides of the membrane at 
T = -24 hours (not shown). TRPV4 agonist GSK1016790A was added to basolateral side of 
the membrane only at T = 0 minutes. 24-hour incubation is signified by white circles.  
GSK1016790A control is signified by black circles. Error bars signify mean ±S.E.M. for 
number of experiments indicated. SCC = short circuit current. * = p < 0.05 against control. 
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Figure 4.9 Pre-treatment of PCP-R cells with PDTC 24 hrs pre-TRPV4 agonist addition. 
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Figure 4.10: Pre-treatment of PCP-R cells with arachidonic acid (AA) at 10-minutes and AA 
metabolism inhibitors at 20-minutes prior to TRPV4 agonist addition. Effect on transepithelial 
ion flux and conductance was measured. AA was added to the PCP-R media on both basolateral 
and apical sides of the membrane at T = -10 minutes. Cyclooxygenase and lipoxygenase 
inhibitor ETYA was added to the PCP-R media on both basolateral and apical sides of the 
membrane at T = -20 minutes. Cytochrome P450 inhibitor SKF-525A was added to the PCP-
R media on both basolateral and apical sides of the membrane at T = -20 minutes. TRPV4 
agonist GSK1016790A was added to basolateral side of the membrane only T = 0 minutes. AA 
pre-treatment is signified by white circles. ETYA pre-treatment is signified by grey circles.  
SKF-525A pre-treatment is signified by dark grey circles. GSK1016790A control is signified 
by black circles. Error bars signify mean ±S.E.M. for number of experiments indicated. SCC = 
short circuit current. * = p < 0.05 against control. τ = p < 0.05 against ETYA pre-treatment in 
SCC graph. τ = p < 0.05 against AA pre-treatment in Conductance graph. Ψ = p < 0.05 against 
ETYA pre-treatment in Conductance graph. 
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Figure 4.10 Pre-treatment of PCP-R cells with AA or metabolites pre-TRPV4 agonist. 
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Figure 4.11: Pre-treatment of PCP-R cells with arachidonic acid metabolite 5,6-EET at 10-
minutes prior to TRPV4 agonist addition. Effect on transepithelial ion flux and conductance 
was measured. 5,6-EET was added to the PCP-R media on both basolateral and apical sides of 
the membrane at T = -10 minutes. TRPV4 agonist GSK1016790A was added to basolateral 
side of the membrane only at T = 0 minutes. 10-minute incubation is signified by white circles.  
GSK1016790A control is signified by black circles. Error bars signify mean ±S.E.M. for 
number of experiments indicated. SCC = short circuit current. 
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Figure 4.11 Pre-treatment of PCP-R cells 5,6-EET 10-min pre-TRPV4 agonist addition.  
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 ADDITIONAL DATA 
5.1 TRPV4 in the Choroid Plexus 
Because TRPV4 is hypothesized to be a major contributor to the development of hydrocephalus 
in our Wpk rat model, it was important to discover its location and relative expression levels in the 
CP. Therefore, using immunohistochemistry of brain tissue slices from hydrocephalic TMEM67 
(-/-) and wild type (WT) animals, I was able to visualize and localize CP (Figure 5.1, yellow arrows) 
and TRPV4 (green) in the rat brains, with DAPI nuclear staining for orientation of individual cells. 
From these sections, I found that at birth (P0) expression levels of TRPV4 in hydrocephalic rats 
(Figure 5.1, B) were similar to that of the wild type animals (Figure 5.1, A). However, as the 
animals develop to P15, this expression appeared to increase in the hydrocephalic rat (Figure 5.1, 
D) while TRPV4 remained unchanged in the wild type animals (Figure 5.1, C). Furthermore, in 
wild type animals there was no detectable TRPV4 expression in the ependymal cells lining the 
ventricle (Figure 5.1, orange arrows). However, in the hydrocephalic rats, the ependymal cells did 
show detectable expression of TRPV4, suggesting further increases in TRPV4 expression.  In both 
phenotypes, TRPV4 localized to the apical membrane of the choroid plexus, with some localized 
intracellularly. It is possible that the intracellular TRPV4 can be stimulated to migrate into the 
apical membrane. This stimulus could include activators of TRPV4, such as pressure changes or 
inflammatory mediators. However, whether this occurs and whether there are differences in the 
extent of migration of the channel between phenotypes has yet to be proven. 
 
Further experiments determined the molecular effects of the TRPV4 antagonist, RN-1734, in the 
CP of treated TMEM67(-/-) rats. Again, utilizing immunofluorescence staining for TRPV4, the 
level of expression in RN-treated rats differed dramatically from that in untreated animals. Unlike 
the expression seen in untreated animals in which TRPV4 completely encompasses the apical 
membrane (Figure 5.2, D & F), the RN-treated CP had sporadic expression along the apical 
membrane with more intracellular expression (Figure 5.2, E). There also appeared to be a decrease 
in expression levels compared to the untreated affected animal. Assuming TRPV4 in involved in 
the movement of ions across the CP epithelium, this implies that antagonizing TRPV4 is causing 
a decrease in ion movement and therefore a decrease in CSF production. Furthermore, in most 
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cases, it appeared as though the remaining apical expression occurred in protruding sections of the 
CP. As the drug was transported through the bloodstream, it is possible that these were areas where 
the capillaries were unable to efficiently reach, thus the blood-borne drug was less effective.  
 
I also returned to claudin-1 expression (as seen in Chapter 3) to compare how the tight junctions 
were affected by the TRPV4 antagonist. When visualizing claudin-1, the protein appeared to be 
more expressed in the RN-treated hydrocephalic rat (Figure 5.2, B) than in the hydrocephalic 
untreated animals (Figure 5.2, A) but not as prominent as in the WT untreated rat (Figure 5.2, C). 
Again, areas of more defined apical expression appeared sporadic, similar to that seen with TRPV4 
in the antagonist-treated animal. While the tight junctional protein did not appear to be as intact as 
the wild type, there appeared to be slight improvement as the protein began to express apically 
once more. This suggests that there was less strain on the barrier and, therefore, the resistance of 
the monolayer likely remained intact. This finding can also be seen in the CP cell line when 
pretreated with RN-1734 (data not shown). These data also imply that tight junction integrity is 
connected to TRPV4 expression on the apical membrane. These experiments were repeated in two 
different animals. 
 
Combined, these data suggest that the mechano- and osmo-sensitive cation channel plays a major 
role in homeostatic CSF production as well as in the formation of hydrocephalus. 
5.2 Characterizing the PCP-R cell line 
In order to determine the presence of various ion channels and proteins in the PCP-R cell line and 
to better characterize the cells, I performed RT-PCR to detect mRNA of receptors and proteins of 
interest (Figure 5.3). Gapdh was used as the positive control in all instances. 
 
Initially, I wanted to determine whether our cell line contained the three different Na+/K+ ATPase 
subunits. The Na+/K+ ATPase has been reported as being particularly important for setting up ion 
gradients in the production of CSF (1). As previously stated in Chapter 1, this is due to the fact 
that in the choroid plexus, the Na+/K+ ATPase is known to be located on the apical membrane. 
However, in the rest of the body, the Na+/K+ ATPase is located on the basolateral membrane. It 
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has been reported that the β-2 subunit is responsible for this opposite targeting (2). The unique 
location of this transporter necessitated characterizing it in our cell line. From this experiment, I 
was able to determine that the cell line does show mRNA of two of the three subunits found in the 
Na+/K+ ATPase, α-1 and β-2. The subunit α-3 was not present (Figure 5.3A). As expected, the 
presence of the β-2 subunit suggests that the channel is able to localize to the apical membrane. 
 
To better define the tight junction properties of our cell line, I also tested for various claudin 
isoforms. Claudins come in two different varieties: barrier-forming and pore-forming. For RT-
PCR, claudins-1, -2, -3, -4, and -10 were examined and all but claudin-10 were present (Figure 
5.3B). Of these, claudins 1, 3, and 4 are barrier-forming, and claudins 2 and 10 are pore-forming. 
Specifically, these barrier-forming and pore-forming claudins decrease and increase permeability 
to cations, respectively (3). This is important because we and others have shown that activation of 
TRPV4 causes a change in permeability (4). Exactly how these claudins may change during 
hydrocephalus and in response to TRPV4 agonists is unknown but may be the topic of future 
studies. 
 
In the WNK pathway, the kinase SPAK plays an integral role for the regulation of various ion 
channels, importantly including the NKCCs, NCC, and KCCs, as previously stated in Chapter 1(5, 
6). Due to the multitude of related pathways through which SPAK is involved in ion transportation, 
this kinase is an important target of study in the hydrocephalus field. Therefore, I tested whether 
the gene which encodes the protein was present in the PCP-R cells. I found that the gene for the 
kinase SPAK, Stk39, was, indeed, present in the cell line (Figures 5.3C).  
 
These characterization studies of the PCP-R cells help to better understand and confirm the impact 
this cell line can have as a CP model. By comparing these findings to those in vivo, we are also 
able to determine the viability as a comparable in vitro model. 
5.3 SPAK and Associated Channels in the Choroid Plexus 
SPAK has been reported as playing a role in the hypersecretion of CSF in intraventricular 
hemorrhage (IVH). The TLR4-dependent kinase phosphorylates and activates NKCC1, a Na-K-
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Cl cotransporter also implicated in CSF production on the apical membrane of the CP epithelium 
(5). In hyperosmotic conditions, SPAK transcription is increased due to an increase in NF-κB 
binding and subsequent SPAK activation (6). Therefore, I determined this protein to be of interest 
and stained P15 Wpk rat brains for SPAK expression. From this, I found that SPAK was increased 
in the hydrocephalic animals. I also found that treatment of the hydrocephalic rats with the TRPV4 
antagonist, RN-1734, decreased SPAK expression to a level comparable to that seen in the wild 
type (Figure 5.4). 
 
Due to the increase in SPAK seen in the hydrocephalic animals and the fact that SPAK is known 
to phosphorylate and activate NKCC1, I stained for phosphorylated NKCC1 (pNKCC1) in the 
PCP-R cells, untreated and treated for 10 minutes with the TRPV4 agonist, GSK1016790A (Figure 
5.5). I found that pNKCC1 was present in the lateral junctions of the cells and that pNKCC1 
intensity increased when treated with TRPV4 agonist. This increase could be due to a TRPV4-
dependent increase in SPAK, leading to increases in the phosphorylation of NKCC1.  
 
Based on these data linking TRPV4 and SPAK activity, I inhibited SPAK and the redundant kinase, 
OSR1, in the PCP-R cells prior to adding TRPV4 agonist using an inhibitor called Rafoxanide 
(Figure 5.6). Interestingly, inhibition of SPAK/OSR1 causes significant changes to both 
transepithelial ion flux and barrier permeability prior to activation of TRPV4. This can be 
attributed to SPAK and OSR1’s role in other ion channels, such as the NKCCs, KCCs, and NCC 
(7). After addition of the TRPV4 agonist, there was a substantial inhibition of TRPV4-mediated 
ion flux as well as a significant increase in conductance with SPAK/OSR1 inhibition alone 
followed by a leveling after TRPV4 agonist addition.  
 
Together, these data suggest a very strong correlation between the WNK pathway, SPAK, and 
TRPV4. The connection is likely due to the interaction between both SPAK and TRPV4 with other 
important ion channels believed to regulate CSF production. However, more experiments will need 
to be conducted in order to further elucidate this connection. 
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5.4 Microglia in Wpk rat brain 
Determining whether inflammation is taking place in our hydrocephalic model is an integral piece 
to discovering the underlying cause of the disease. Sites of injury and neuronal death can cause of 
the activation of the central nervous system’s macrophage-like immune cells, microglia. Activated 
microglia release pro-inflammatory cytokines and activate other cells of the immune system (8). 
It is possible that the activation of microglia and subsequent inflammatory pathways is a 
contributing factor to the pathology of hydrocephalus. To test this theory, I stained adult and 
juvenile Wpk brains for activated microglia and found that in the older, severely affected 
heterozygous hydrocephalic brain (P356) activated microglia are increased around the 
subventricular and hippocampal regions (Figure 5.7). These areas are of interest as they are areas 
of neurogenesis (9). 
 
Following this initial discovery, I repeated the experiment in even older (P460) WT and 
TMEM67(+/-) brains (Figure 5.8). However, the heterozygous brain tested was not as severely 
affected as the P356 brain previously observed and was therefore labeled as having “mild” 
hydrocephalus. The mild hydrocephalic adult did not exhibit the same microglial activation as seen 
in the severely hydrocephalic animal. This could signify that the microglia activation is dependent 
on the severity of the condition. Interestingly, the WT control brain did show an area of microglial 
activation in the region of the hippocampus. However, these microglia did not appear to be 
activated due to hydrocephalus. Rather, this instance could be due to other outside means, such as 
hemorrhage or trauma in the area.  
 
In order to test whether disease severity was the causative effect of microglia activation, I repeated 
the experiment again in P330 brains with the WT having small ventricles and the TMEM67(+/-) 
having large ventricles (Figure 5.9). In this experiment, no difference in microglia activation was 
seen between the WT and hydrocephalic TMEM67(+/-). It should be of note that these “large” 
ventricles were indeed larger than the “mild” hydrocephalus seen in the P460 animal. However, 
these “large” ventricles in the P330 animal were still smaller than the “severe” hydrocephalus seen 
in the P356 animal. Therefore, it is possible that the severity of the disease could still be a 
contributing factor to inflammation. 
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In addition to the adult animals, I also stained for microglia in the juvenile (P15) WT, 
TMEM67(+/-), and TMEM67(-/-) animals (Figure 5.10). Considering that the homozygous 
animals have the most severe hydrocephalus, this experiment would best answer the question of 
whether the severity of hydrocephalus determined the amount of microglia activation. However, 
no difference was observed between the three genotypes. To confirm these results, WT and 
homozygous brains at P17 were stained for activated microglia with the idea that the 
hydrocephalus would be worse at P17 compared to P15 (Figure 5.11). While the hydrocephalus 
was indeed worse in the affected animal, there was still no difference seen between the WT and 
homozygous animal. Therefore, the conclusion must be made that severe hydrocephalus does not 
cause activation of microglia. 
5.5 Discussion 
These additional experiments complement the data found in previous chapters in that the reasoning 
and results behind the previous data becomes clearer. TRPV4 appeared to be increased in the 
hydrocephalic animals. This suggests that TRPV4 is a contributing factor towards the disease. 
Therefore, we use a TRPV4 antagonist drug to combat the hydrocephalus, and, as previously 
mentioned in Chapter 1, we have seen promising results of attenuation in the head dimensions of 
treated animals. In addition to this, we see decreases in TRPV4 expression in the CP epithelial 
upon antagonism and partial restoration of the blood-CSF barrier as evidenced by increases in 
claudin-1 expression in these treated animals. This implies that the drug treatment is effective. 
As demonstrated in Chapters 2 and 3, we have also strived to characterize efficient in vivo and in 
vitro hydrocephalus and CP models through the Wpk rat and the PCP-R cell line, respectively. By 
further characterizing the PCP-R cells through RT-PCR and confirming the presence of polarizing 
and barrier-forming channels, we have shown that this model is, indeed, an effective model for 
studying this interesting tissue type.  
 
Several different pathways likely interact with TRPV4 or are in some way modulated by its activity. 
Deciphering these various pathways and how they are all connected is an important aspect to 
understanding how TRPV4 plays a role in the secretion and/or absorption of CSF. Therefore, the 
discovery that TRPV4 and the WNK pathway can have significant effects on each other provides 
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a crucial key to the mechanism of the ion channel’s function. These data suggest that, in addition 
to the calcium-sensitive potassium channels mentioned in Chapter 3, TRPV4 can potentially act 
on various other ion channels through the kinase, SPAK, providing a means of transepithelial ion 
flux, as evidenced by the increase in activated phosphorylated NKCC1 in the PCP-R cells when 
pretreated with the TRPV4 agonist. Furthermore, it appeared that not only is TRPV4 necessary for 
SPAK expression, specifically on the apical membrane of the CP where it is potentially co-
expressing with and activating NKCC1, but SPAK/OSR1 is also necessary for TRPV4-mediated 
ion flux and permeability changes. Together, this implies that TRPV4 and SPAK are dependent 
on each other. 
 
Finally, as a continuation from Chapter 4, I showed that TRPV4 can be modulated by increases in 
pro-inflammatory cytokines and mediators. Therefore, considering that TRPV4 has been shown to 
be increased in the hydrocephalic Wpk rats, I hypothesized that this increase was due to 
inflammation in the brain due to hydrocephalus. As a means to measure inflammation, microglia 
activation was observed in several ages and brain regions of hydrocephalic Wpk rats, and I was 
surprised to find that of 23 animals tested, only one showed signs of inflammation likely due to 
hydrocephalus. While this cannot rule out that inflammation from different origins is present, such 
as from neutrophils or monocytes, in any of these animals, it does suggest that inflammation is not 
present due to microglial activation. 
Based on these data, we can make further assumptions and come another step closer towards the 
mechanism of TRPV4 as well as the pathology and development of hydrocephalus. 
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Table 5.1 Primer sequences used for RT-PCR with corresponding product sizes (bp).  
Three different primer sets were generated and tested for each gene. Primers included in this 
table were utilized for Figure 5.3. Gapdh was used as a positive control. 
 
Sus Scrofa 
gene 
Protein Primer Sequences 5' - 3' Product 
Size (bp) Forward Primer Reverse Primer 
Atp1a1 NaK ATPase α1 TTCCCTTCAACTCCACCAACAA TTCAAGATGTCATCCAGCTGCT 610 
Atp1a3 NaK ATPase α3 AGAAGGTGAGAAGATGCAGGTG CTCCAGGTTTTTCACAAGGCAG 568 
Atp1b2 NaK ATPase β2 CTTCCTCACCACTGTCTCTGAC TTGCTCCTGCGTAGAAGTTGAT 395 
Cldn1 CLDN1 CTACGCTGGTGACAACATTGTG CACGTAGTCTTTCCCACTGGAA 532 
Cldn2 CLDN2 CTCTCGGCCTCCAACTTGTAG AGTAGAGAGCCTCTCCGATCTC 489 
Cldn3 CLDN3 CTTCATCGGCAGCAGCATTATC CCAGCAGAGAGTCGTACACTTT 113 
Cldn4 CLDN4 CTTCATCGGCAGCAACATCG CTGAGTAGGGCTTGTCGGTAC 482 
Cldn10 CLDN10 CAGGCATGTCGAGGACTTATGA CCTCCTCCGTGATACTTTGTCC 410 
Stk39 SPAK TAGCAACAGGGGGTGATGTTAC GGAAGTTCTCACTCAGGTCCAG 432 
Gapdh GAPDH TTTTAACTCTGGCAAAGTGGAC CTCTTTGGGCTATGTCTGGTGT 884 
  
166 
 
 
 
Figure 5.1 Immunofluorescence of TRPV4 in the Wpk rat CP. 
Brain tissue was sectioned at 20 µm and incubated with primary antibody for TRPV4 (1:200 
dilution, Alomone anti-TRPV4). Images correspond with wild type (WT, A & C) and 
hydrocephalic (TMEM67 (-/-), B & D) animals at birth (P0, A-B) and at the time of sacrifice (P15, 
C-D). DAPI staining allows for visualization of nuclei (500ng/mL, Sigma). Images were taken on 
a Leica TCS SP8 (upright high-speed multiphoton and confocal imaging system). n=3. Scale bars 
= 50 µm.  
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Figure 5.2 Immunofluorescence of Claudin-1 and TRPV4 in RN-1734-treated P15 Wpk CP. 
Immunofluorescence of Claudin-1 (A-C) and TRPV4 (D-F) in P15 Wpk choroid plexus treated 
with TRPV4 antagonist RN-1734. Brain tissue was sectioned at 20 µm and incubated with primary 
antibody for TRPV4 (1:200 dilution, Alomone anti-TRPV4) and for the tight junction protein, 
claudin-1 (1:100 dilution, Abcam anti-Claudin 1). DAPI staining allows for visualization of nuclei 
(500ng/mL, Sigma). Images were taken on a Leica TCS SP8 (upright high-speed multiphoton and 
confocal imaging system). Images from TMEM67 (-/-) and WT were taken from Figures 2.8 and 
5.4. n=2. Scale bars = 50 µm. 
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Figure 5.3: RT-PCR in PCP-R epithelial cells. A) mRNA is present for the Na+/K+ ATPase 
subunits α1 and β2, but not α2. B) Results for the tight junctional proteins claudin-1-4, and 10. 
Claudins-1-4 were present. Claudin-10 was not present. C) The gene which transcribes the 
kinase SPAK, Stk39, is present in the PCP-R cell line. Gapdh was utilized as positive controls 
for each gel. Band product sizes can be found in Table 5.1. Ladder = 1kb. 
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Figure 5.3 RT-PCR in PCP-R epithelial cells. 
  
C) 
B) 
A) 
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Figure 5.4 Immunofluorescence of SPAK in P15 Wpk CP treated with RN-1734. 
Immunofluorescence of SPAK in P15 Wpk WT, TMEM67(-/-), and TMEM67 (-/-) CP treated 
with RN-1734. Brain tissue was sectioned at 20 µm and incubated with primary antibody for SPAK 
(1:50 dilution, Cell Signaling Technology Anti-SPAK). DAPI staining allows for visualization of 
nuclei (500ng/mL, Sigma). Images were taken on a Leica TCS SP8 (upright high-speed 
multiphoton and confocal imaging system). n=3. Scale bars = 50 µm. 
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Figure 5.5 Immunofluorescence of pNKCC1 in TRPV4 agonist (GSK)-treated PCP-R cells. 
Cells were stained with DAPI (blue) to visualize nuclei and anti-pNKCC1 antibody (1:200 dilution, 
Millipore anti-pNKCC1). Treated cells were pre-incubated with TRPV4 agonist, GSK1016790A 
(3nM), for 10 minutes before fixation and staining. Negative control cells were stained with DAPI 
and secondary antibody only. n= 3. Scale bars = 25µm. 
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Figure 5.6: Pre-treatment of PCP-R cells with SPAK/OSR1 inhibitor Rafoxanide at 10 minutes 
prior to TRPV4 agonist addition. Effect on transepithelial ion flux (A) and conductance (B) 
was measured. Rafoxanide was added to the PCP-R media on both basolateral and apical sides 
of the membrane at T = -10 minutes. TRPV4 agonist GSK1016790A was added to basolateral 
side of the membrane only at T = 0 minutes. 10-minute incubation is signified by white circles.  
GSK1016790A control is signified by black circles. Error bars signify mean ±S.E.M. for 
number of experiments indicated. SCC = short circuit current. * = p < 0.05 against control. 
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Figure 5.6 PCP-R epithelial cells pretreated with SPAK/OSR1 inhibitor Rafoxanide. 
A) 
B) 
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Figure 5.7 Microglia in P356 Wpk WT and TMEM67 (+/-) rats. 
Brains were sectioned at 40 µm and incubated with primary antibody for Iba1 (1:5000 dilution, 
Wako anti-Iba1). DAB was used as a chromogen to visualize activated microglia (brown). 4x and 
10x magnifications were used. Scale bars = 250 µm. 
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Figure 5.8: Microglia in P460 Untreated Wpk WT (A) and TMEM67(+/-)-Mild (B) rats. Brains 
were sectioned at 40 µm and incubated with primary antibody for Iba1 (1:5000 dilution, Wako 
anti-Iba1). DAB was used as a chromogen to visualize activated microglia (brown). 4x and 10x 
magnifications were used. Two different brain regions were visualized: hippocampal (left) and 
subventricular (right). Scale bars = 250 µm. 
 
176 
 
Figure 5.8 Microglia in P460 Wpk WT and TMEM67 (+/-) rats. 
A) 
B) 
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Figure 5.9: Microglia in P330 Wpk WT (A) and TMEM67 (+/-)-Severe (B) rats. Brains were 
sectioned at 40 µm and incubated with primary antibody for Iba1 (1:5000 dilution, Wako anti-
Iba1). DAB was used as a chromogen to visualize activated microglia (brown). 4x and 10x 
magnifications were used. Two different brain regions were visualized: hippocampal (left) and 
subventricular (right). Scale bars = 250 µm. 
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Figure 5.9 Microglia in P330 Wpk WT and TMEM67 (+/-) rats. 
  
A) 
B) 
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Figure 5.10 Microglia in P15 Wpk WT, TMEM67 (+/-) and TMEM67 (-/-) rats. 
Brains were sectioned at 40 µm and incubated with primary antibody for Iba1 (1:5000 dilution, 
Wako anti-Iba1). DAB was used as a chromogen to visualize activated microglia (brown). 4x and 
10x magnifications were used. Scale bars = 250 µm. 
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Figure 5.11 Microglia in P17 Wpk WT and TMEM67 (-/-). rats. 
Brains were sectioned at 40 µm and incubated with primary antibody for Iba1 (1:5000 dilution, 
Wako anti-Iba1). DAB was used as a chromogen to visualize activated microglia (brown). 4x and 
10x magnifications were used. Scale bars = 250 µm. 
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 SUMMARY 
Treatment options for hydrocephalus patients are dim. Currently, the only approved methods of 
treatment are ineffective and require invasive, life-threatening brain surgery.  In order to discover 
a suitable alternative pharmacotherapy for hydrocephalus, we need to understand the 
mechanisms of the disorder to determine the best way to combat it.  
 
By characterizing and establishing two genetic in vivo hydrocephalic rodent models, the fast-
progressing homozygous and slow-progressing heterozygous Wpk rat, we and other research 
groups can utilize this animal to study the development of the model analogous to both pediatric 
and geriatric hydrocephalus (1). Several previous in vivo models of hydrocephalus utilize kaolin 
to induce hydrocephalus by injecting the chemical into the cisterna magna or the ventricular 
space. However, this method causes a breakdown of the epithelial lining of the ventricles and CP 
and therefore, does not effectively mimic real instances of hydrocephalus (2). As the Wpk rat has 
a genetically-based hydrocephalus, we can study the disease in a model that is similar to 
instances of hydrocephalus in humans.  
 
While the in vivo model is excellent for studying the macroscale characteristics of hydrocephalus 
and the CP, we have also established an effective in vitro model for studying the molecular 
mechanisms for CSF production by means of the PCP-R cell line. This cell line allowed us to 
determine drug effects on transepithelial ion flux and barrier permeability, both necessary 
aspects to CSF production and CP integrity as part of the blood-CSF barrier. The high resistance 
property of this continuous cell line as well as its ability to grow as a polarized monolayer better 
imitates the CP barrier seen in vivo than primary culture. Thus, we can conclude that the PCP-R 
cell line is an effective means of studying the molecular mechanisms of the CP epithelia.  
Furthermore, from the characterization studies presented in this thesis, we are not only able to 
distinguish ion channels, genes, and proteins specifically in the CP epithelium as we are able to 
determine potential targets for drug treatment in the CP as well.  Specifically, we identified the 
ion channel, TRPV4, as a promising target for regulation of CSF production. Utilizing our 
hydrocephalic rat model, I showed that TRPV4 is upregulated in the affected animals. As such, 
we turned to the in vitro model to determine TRPV4’s molecular function. As evidenced, we 
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determined various effectors involved with TRPV4 and further elucidated the mechanisms 
behind the ion channel’s function in the CP. From Chapter 3, it was discovered that the 
transepithelial ion flux mediated by TRPV4 is resultant of activation of the calcium-sensitive 
potassium channel, IK, likely due to the influx of calcium into the cell via TRPV4. Activation of 
the IK channel allows potassium ions to be secreted into the luminal space, thus increasing 
extracellular potassium. In addition to this, from Chapter 5, I was able to determine that TRPV4 
can potentially interact with the kinase SPAK to activate downstream ion channels. Previous 
works have concluded that NKCC1 is the predominant channel responsible for ion movement 
related to CSF production (3, 4). Indeed, activated pNKCC1 appeared upregulated in response to 
TRPV4 agonism in the PCP-R cells. Thus, this leads to the conclusion that TRPV4 can activate 
several ion channels capable of contributing to the regulation of CSF production, highlighting the 
cation channel’s potential as a drug target. 
 
Finally, I wanted to determine how and why TRPV4 would be upregulated during hydrocephalus 
and hypothesized that inflammation in the brain was the causative agent. While characterizing 
the PCP-R cells, all known TLRs were present, meaning the CP epithelia can respond to and 
produce various cytokines. Upon testing the effects of various pro- and anti-inflammatory 
cytokines and inflammatory mediators on TRPV4-mediated transepithelial ion flux and barrier 
permeability in the cells, I found that pro-inflammatory mediators attenuated the effects of 
TRPV4 stimulation. Upon further study, I also clarified the interaction between TRPV4 and the 
inflammatory mediator AA and its metabolites. While AA is claimed to activate TRPV4 (5), my 
studies suggested that TRPV4 is inhibited by increases in AA. Rather, I have found that AA 
metabolites are indeed the activators of TRPV4-mediated changes in the cell, including ion flux 
across the epithelium. Specifically, metabolism of AA into EETs by the CYP-450 epoxygeneases 
appeared to be the most important mediator, as its inhibition prevented all TRPV4-mediated 
changes, while the other metabolites minorly affect TRPV4 function. Together, this implies that 
TRPV4 is affected by inflammation in that inflammation downregulates TRPV4. This could 
mean that inflammation is utilized to control TRPV4 activity and therefore is not the causative 
agent of TRPV4 activation.  
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To then determine whether inflammation was present in our animal model, I sought to observe 
inflammation using immunohistochemistry for activated microglia. From these data, the 
conclusion was made that there were no distinguishable signs of inflammation in the affected 
animals due to microglia activation. Therefore, inflammation is likely not causing an increase in 
TRPV4 expression in either of our rat models of hydrocephalus.  
 
In conclusion, with 6.4 million individuals across the globe and of all walks of life affected by 
hydrocephalus, there is a need for an effective, non-invasive treatment (6). With these data 
through the use of tissue and cellular models more analogous to the disease in humans, I hope to 
bring the scientific community one step closer to finding a suitable treatment. 
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